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ABSTRACT 
Acquired Immunodeficiency Syndrome (AK)S) is a deadly pandemic disease caused 
by a retrovirus known as human immunodeficiency virus type 1 (HIV-1). Three HIV-
1 enzymes are critically essential to the life cycle of the HIV; namely HIV reverse 
transcriptase (RT), HIV protease (PR), and HIV integrase (EN). The chemotherapeutic 
strategies have therefore been focused on the development of inhibitors against these 
viral enzymes. More recently, the HIV-1 PR has became an important target. Several 
drugs have been approval in US for AIDS therapy based on the knowledge of HrV-1 
PR. However, one of the major obstacles to the long-term treatment of AEDS is the 
remarkable mutation of HIV to most, if not all, of the clinically used 
chemotherapeutic agents. Therefore, there is an ongoing need for new, structurally 
diverse anti-HIV agents, which are less toxic and affordable to all AE)S patients, 
especially in the developing countries. In this study, two different aspects were used to 
determine the useful tools for anti-HIV-1 PR. In the first part, we used Traditional 
Chinese medicinal herbs to demonstrate the inhibitory activity on HIV-1 PR. Chinese 
medicinal herbs have been shown to be effective in inhibiting the growth of HIV in 
vitro. In this study, they were examined for inhibitory effects on HIV-1 PR. The 
aqueous and methanol extracts of thirty-one herbs traditionally used as anti-fever 
remedies in China were screened for their in vitro inhibition on human 
immunodeficiency virus type-1 protease (HIV-1 PR). Among the herbal extracts 
examined, the methanol extract of Woodwardia unigemmata exhibited over 90% 
inhibition at 200p.g/ml. Then the crude methanol extract was fractionated through 
Sephadex LH-20 gel chromatography and reverse-phase HPLC respectively, which 
resulted in the isolation of an active constituent of near homogeneity. Analytical TLC 
analyses of known classes of phyto-chemicals indicated that the active constituent(s) 
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may be a glycoalkaloid-like compound. Molecular weight determination by 
electrospray mass spectrometry suggested that the active compound is approximately 
6kDa in size. The purified extract inhibited HIV-1 PR in-vitro with an IC50 of ~15p.M. 
Acid hydrolysis aimed to remove the carbohydrates resulted in a decrease in 
inhibitory activity. The inhibitory activity was, however, not affected by either a - or 
p- (1 — 4)-glucosidase digestion indicating that the sugar moieties associated with the 
alkaloid may not through a- or P-glucosidic linkages. The active constituent has little 
inhibitory activity towards other aspartic proteases, renin and pepsin. In the second 
part of this study, an in vitro selection procedure, SELEX (Systematic Evolution of 
Ligands by EXponential Enrichment) was employed to isolate RNA aptamers that 
bind to HrV-1 PR immobilized on a solid support. Remarkably high-affinity RNA 
motif that binds HFV-1 PR were isolated by the SELEX from RNA populations of 
randomized at 40 positions. After 15 rounds of in vitro selection, the selected ligands 
were analyzed and revealed a consensus sequence, embedded in primary sequences 
with at least 10"^ M affinity. The minimal sequences required for the ligands to bind to 
HIV-1 PR were also determined. A repeated element AGAGA was conserved in 41 
out of 87 isolated RNA ligands sequences. We also demonstrated that the presence of 
at least one of the homo-purine sequence, AAA or GGG, was essential for the binding 
of RNA ligands to HIV-1 PR. Moreover, we compared the inhibitory ability of 
ligands before and after the selection. At equal concentrations of RNA inhibitor to 
HIV-1 PR, the PR is significantly inhibited by the selected ligands. Although the 
sequences that are responsible for such high inhibition activity are still not identified. 
This experiment highlights the power of SELEX to yield highly specific ligands that 
inhibit the activity of target molecules. Such ligands may provide therapeutic reagents 





















• R O D U C T I O N 
1.1 Acquired immunodeficiency syndrome (AIDS) 
1.1.1 History of AK)S 
In 1981, a drug technician at the Center for Disease Control and Prevention 
(CDC) in the United States (US) noticed an unusually high number of requests for the 
drug pentamidine used in the treatment of Pneumocystis carinii pneumonia (PCP). This 
led to a scientific report of PCP occurring unusually in five gay men in Los Angeles. The 
search began for the cause not only of the PCP in gay men in Los Angeles, but also of the 
Kaposi's Sarcoma (KS) occurring in gay men in New York. At that time the poppers or 
nitrate inhalants was believed as the leading candidate, and very few suggested that it was 
caused by an infectious agent (Center of Diseases Control, June 5, 1981). 
In 1982，this syndrome was called GRE) (Gay-Related Immune Deficiency) by 
some scientists and it became clear that it was caused by an infectious agent, possibly a 
virus that could be spread through blood. An article subsequently reported in the Wall 
Street Journal that GRK) was also found in women and male heterosexual drug users. 
Because of it, the syndrome was given a new name AH)S which stands for Acquired 
Immune Deficiency Syndrome. The illness is characterized by a failure, or deficiency, of 
the immune system (Center of Diseases Control, September 3，1982). 
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In 1983, medical researchers at the Institute of Pasteur in France announced that 
they had isolated a new virus causing AJDS. The virus was called lymphadenopathy-
associated virus (LAV). In May 1983 a report of AIDS occurring in children suggested 
quite incorrectly the possibility of casual household transmission. Later in the year the 
number of children with ADDS had increased, and it was generally accepted that the 
children had acquired the infection from their mothers in the womb or during birth. It also 
became clear that the virus, which caused AE)S, could be transmitted through blood 
transfusions (Center of Diseases Control, May 13, 1983). 
In 1984, the US Government announced that Dr Robert Gallo, at the National 
Cancer Institute (NCI) had isolated the retrovirus, which caused AEDS, and that it was 
• named HTLV-III (Center of Diseases Control, July 13, 1984). 
In 1986，it became clear that the viruses LAV and HTLV-HI were actually from 
the same host. An international committee ruled that both names should be dropped and 
replaced by the new name human immunodeficiency virus (HIV) (Center of Diseases 
Control, September 26，1986). 
1.1.2 Definition ofAEDS 
ADDS is a deadly pandemic disease caused by a retrovirus known as HFV (Barre 
et al., 1983; Popovic et al., 1983). The definition of ADDS is defined by the Center for 
Disease Control and Prevention (CDC) in United States of America. AJDS refers to an 
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adult or adolescent age 13 years or older showing symptoms on one of 25 conditions 
(Table 1.1 shows the symptoms frequently associated with AHDS in the United States) 
indicative of severe immunosuppression associated with HIV infection, or HIV infection 
in an individual with a CD4+ T cell count less than 200/cells per cubic millimeter (mm^) 
of blood (Center of Diseases Control, 1992). 
In children younger than 13 years, the definition of AEDS is similar to that in 
adolescents and adults, except that lymphoid interstitial pneumonitis and recurrent 
bacterial infections are included in the list of AK)S-defining conditions. 
Table 1.1: ADDS-Indicator Conditions in Adults and Adolescents with AEDS, 
- Reporting in 1998, United States' 
Most Frequently Reported Condition* Number of Cases Percent of Cases 
Severe HIV-related immunosuppression 40,611 85 
Pneumocystis carinii pneumonia 7,485 16 
HIV wasting syndrome 3,757 8 
Esophageal candidiasis 3,054 6 
M. Tuberculosis infection 1,552 3 
Recurrent pneumonia 1,140 2 
Kaposi's sarcoma 1,099 2 
Severe herpes simplex 1,039 2 
Crytococcosis 931 2 
HIV encephalopathy 9 ^ 2 
* Many patients with AEDS have more than one condition (Center of Diseases Control, 
1992). 
1 Data from the Centers for Disease Control and Prevention, (http://www.cdc.gov/) 
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1.1.3 mV/AH)S Around the World^ 
According to the estimation from the Joint United Nations Programme on 
HIV/AK)S (UNAroS) and the World Health Organization (WHO) in 1999, 32.4 million 
of adults and 1.2 million of children would be living with AEDS. About 2.6 million HrV 
infected patients died from AK)S. 
The overwhelming majority of people with HIV - some 95% of the global total --
live in the developing world. The rate of HIV infection continues to rise in countries had 
inapped poverty, poor health systems and limited resources (UNADDSAVHO, December 
1999). 
1.1.4 HIV/AEDS in Hong Kong 
1.1.4.1 Hong Kong AIDS Update 
The first case of HIV infection in Hong Kong was reported in 1984. The 
Department of Health encouraged physicians to report all newly diagnosed HIV 
infections. This reporting method has been supplemented by a parallel reporting system 
involving laboratories that provide confirmatory HIV tests. By the end of 1999, a total of 
1,359 HIV infections had been reported, bringing the number of annual infections up to 
213 (Figure 1.1) (AJDS Units: Department of Health, 2000). 
2 All the information is adapted from the AIDS epidemic update, published by UNAIDS and WHO in 
December, 1999. 
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Figure 1.1: Number of HIV infections and AE)S by year of report from 1984 to 1999 in 
Hong Kong. Total HIV reported: 1,359. Total AHDS reported: 433. 
All epidemiological statistics were provided by the HIV Surveillance Office of the Hong 
Kong Department of Health. (AH)S Units: Department of Health, 2000) 
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1.1.4.2 AIDS Transmission . 
The chief routes of HIV transmission are by blood^lood product transfusion 
(injection drug user or blood transfusion during operation), unprotected sexual 
intercourse, and mother-to-child (in uterus, during delivery or breast milk). Circulating 
infectious HIV is present in nearly all blood samples taken from HIV-infected individuals 
at all stages of infection. The infected peripheral blood mononuclear cells (each with the 
potential of producing thousands of infectious vims particles daily) and the free 
infectious virus particles present in plasma comprise a large source of virus. 
Approximately 10-30% of specimens of seminal or vaginal fluids from infected 
individuals contain free infectious HIV or HIV-infected cells (CD4 T cells and 
” macrophages) (Dalgeish et al., 1984), with cells probably the major virus source 
(Friedland and Klein, 1987). 
1.1.4.3 Main AIDS Complications Occur in Hong Kong^ 
Pneumocystis carinii pneumonia (PCP) is the most common primary ALDS-
defining illness in Hong Kong, occurring in more than 40% of those in whom HIV 
diagnosis. (AJDS Units: Department of Health, 2000). PCP is readily preventable in 
patients with known HIV infection who are adherent to primary prophylaxis (Center of 
Diseases Control, June 5，1981). Its occurrence therefore reflects a relatively late 
diagnosis or failure to seek medical management in the first place. 
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Mycobacterium tuberculosis is the second common complications in the local 
HIV epidemic. From 1995 to 1996, it is reported tuberculosis has accounted for 20% of 
all reported AEDS cases in Hong Kong. 
Penicilliosis is the third most common primary AHDS-defining condition in Hong 
Kong. About 8% of reported AH)S cases in Hong Kong had penicilliosis as the primary 
AE)S-defining illness. 
Other important primary ADDS-defining illnesses in Hong Kong are candidal 
esophagitis, cryptococcal meningitis and Kaposi's sarcoma commonly occurring in those 
not stimultaneously reported with both HIV infection and AIDS (AIDS Units: 
• Department of Health, 2000). 
1.2 Human Immunodeficiency Virus (HIV) 
1.2.1 Classification ofHIV 
HIV belongs to the retrovirus family, a family of RNA viruses distinguished by 
possession of a viral reverse transcriptase that transcribes viral RNA into provirus DNA 
that is integrated into the host-cell genome (Connor et aL, 1997). Both the exogenous and 
endogenous retroviruses are widely distributed in the vertebrate animal kingdom (from 
reptiles to primates). They are generally host-specific and divided into two subfamilies: 
"oncoretroviruses", with HTLV (human T-cell lymphotropic virus) as the human 
3 All the information is adapted from AIDS Unit, Department of Health, Hong Kong, 2000). 
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prototype; and "lentiviruses", with HIV as the human prototype (Connor et al., 1997; 
Popovic etal., 1983). 
HIV is subdivided into two distantly related types, HIV-1 and HIV-2. HIV-1 is 
the predominant worldwide isolated from individuals with AIDS or at high risks for the 
development of AEDS. HIV-2 is endemic among people in West Africa (Guyader et al., 
1987). The origins of HIV-1 and HIV-2 apparently represent cross-species infections. All 
HIV-1 strains are closely related phylogenetically to a strain of SIV (simian 
immunodeficiency virus) that naturally infects a subspecies of chimpanzee whose habitat 
corresponds to regions in West Africa in which human HIV-1 infection is endemic (Gao 
et al, 1999). A primate reservoir of HIV-2 has also been identified (Guyader et al., 
‘ 1987). 
The strains of HIV-1 that account for the worldwide pandemic of AH)S are 
designated as group M strains. A recently recognized group of HIV-1 viruses that cause 
AIDS but are different from group M strains is called group 0 . The first recognized case 
of HIV-1 group 0 infection in the U.S. was reported recently. HIV-1 group 0 infection is 
not consistently detected by standard assays for HIV antibody (Center of Diseases 
Control, July 5, 1996). 
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1.2.2 The Structure of HIV Virion 
HIV has a diameter o f -110 nanometers and is spherical in shape. The encapsuled 
with a viral envelope is acquired during virion budding. Embedded in the viral envelope 
are proteins known as Env, consists of a cap made of three or four molecules called 
glycoprotein (gpl20), and a stem consisting of three or four gp41 molecules that anchor 
the structure in the viral envelope (Levy, 1994). 
Within the envelope of a mature HIV particle is a bullet-shaped core or capsid, 
p24. The capsid surrounds two single strands of HIV RNA, each of which has a copy of 
’ the virus's nine genes. Three of these, gag, pol and env, contain information needed to 
make structural proteins. The env gene, for example, codes for a protein called gpl60 that 
is broken down by a viral enzyme to form gpl20 and gp41, the components of envelope 
protein (Connor etaL, 1997; Levy, 1994). 
Three regulatory genes, tat, rev and nef, and three auxiliary genes, vif, vpr and 
vpu, contain information necessary for the production of proteins. They are responsible 
for the control of the ability of HIV to infect a cell, producing new copies of virus or 
causing disease. The protein encoded by nef, for instance, appears necessary for the virus 
to replicate efficiently, and the vpM-encoded protein influences the release of new virus 
particles from infected cells (Connor et al., 1997). 
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The core of HIV also includes four viral proteins (p24 - the major capsid protein, 
pl7- a matrix protein, p9 and p7 - bound to two copies of the HIV RNA genome), and 
three viral enzymes (reverse transcriptase, integrase, and protease) essential for viral 
replication (Henderson etaL, 1992). 
< ^ J t 3 t > z Reverse Transcriptase 
^ j ^ ^ p ^ ^ ^ ^ 5 d P r o t e i n 
r ' !| 0 i g — — L i p i d Membrane 
| iU \ \ <«> / 1 ^ 
^ ^ ^ ^ \ , s r „ 
/ � I t i Two strands of viral R N A 
Protease 
Matrix Protein 
Figure 1.2: Diagram of mature HIV virion showing envelope (gpl20 and gp41) in lipid 
bilayer，core protein (p24, pl7, p9, p7), diploid single-stranded HIV RNA, and viral 
enzyme (reverse transcriptase, protease, and integrase) required for replication. (Adapted 
from http://www.hivpositive.CQm/f-HIVvou/l-HIVvou/l-HIVanatomv.html with some 
modification). 
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1.2.3 The HIV Genome 
The 9-kilobase single-stranded HIV RNA genome contains three genes {gag, env, 
pol) essential for retroviral replication. The gag precursor is cleaved to form five virion 
core proteins. They are p9, p25, pl7, pl, and p6 (Henderson et aL, 1992). The pol is 
cleaved to form reverse transcriptase, integrase, and protease. Glycoproteins gpl20 and 
gp41 are produced from env together with some regulatory proteins (Levy, 1994). The 
ends of HIV RNA contain an RNA sequence called the long terminal repeat (LTR). 
Regions in the LTR act as switches to control production of new viruses and can be 
triggered by proteins from either HIV or the host cell (Cullen and Greene, 1989). 
rev tat 
I ~ — — ^ — — I I I I J ' , I , 
LTR gag pol v i f vpu vpr tat rev e n V nef L T R | 
r " H | l l l l V r _ 0 
p55 1^ “^/。I p 2 4 p l 6 p l 5 p l 4 p l 9 / 2 0 g p l 6 0 p 2 8 
~ J ~ pllP66/51p32 l � | •>" 
r + n r ^ 
pl7 p24 pl5 gpl2 gp41 
Figure 1.3: Diagram of the HIV-1 genome and encoded proteins (Adapted from Georgiev 
and Mcgowan, 1993) 
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1.2.4 The LifeCycle ofHIV . 
1.2.4.1 Invasion ofthe Cells 
The chief target cells for HIV infection are human CD4 T-lymphocytes and 
macrophages (Dalgeish et aL, 1984). The CD4 glycoprotein on the surface of these cells 
serves as a high affinity receptor for HIV. An infection is initiated by binding of the 
virion envelope gpl20 to the CD4 receptor on the host cell. The recently discovered co-
receptors (either CCR5 or CXCR4) present on target cells to facilitate HIV entry. CCR5, 
a chemotactic cytokine (beta-chemokine) receptor, is a coreceptor for macrophage (M)-
tropic strains of HIV (Ditzel et aL, 1998) and CXCR4, also a chemokine receptor, is a 
coreceptor for T-lymphocyte (T)-tropic strains of HIV (Doranz et al., 1997). HIV 
infection is initiated by sequential binding of the viral envelope glycoprotein gpl20 to the 
CD4 receptor and one or the other coreceptor and by gp41-mediated fusion of the viral 
envelope with the cell membrane. After uncoating, the viral core and its components -
viral RNA, gag gene proteins, and pol gene enzymes - are released into the cytoplasm 
{Mooreet aL, 1993). 
1.2.4.2 Reverse Transcription 
The cell needs to integrate its genetic material to the host genome, thus the virus 
has to reverse transcribe its viral RNA to DNA. This is accomplished via an enzyme 
known as reverse transcriptase. The viral reverse transcriptase converts the single-strand 
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viral RNA into viral cDNA copy, and then into a viral DNA duplex of two strands 
(Litvak, 1996). 
1.2.4.3 Integration into cell genome 
The viral DNA duplex is transported to the cell nucleus where it is integrated by 
the HIV integrase into the host cell genome as covalently linked HIV provirus DNA. 
Once integrated into the host cell genome as provirus DNA, HIV can establish a virus-
producing infection or a latent infection depending upon critical host factors, particularly 
whether the infected cell is in an activated or resting state. In a permissive cellular 
environment, the provirus DNA is copied by the host cell RNA polymerase II into viral 
" RNA transcripts that become spliced into mRNAs for translation into HYV regulatory 
proteins (Tat, Rev, others) or precursor proteins encoded by the gag, pol, and env genes 
(Engelman etal., 1991; Schwartz etal., 1990). 
1.2.4.4 Protease and assembly to the virus 
The core protein precursor is specifically cleaved by the HIV protease. Once 
assembled, the HIV core containing HIV RNA (2 copies), core proteins (p24, pl7, p9, 
p7), and pol enzymes (reverse transcriptase, integrase, protease) moves to the cell 
surface, and acquiring HIV envelope proteins (gpl20, gp41). Finally, the virion buds 
through the plasma membrane and is released as infectious virus (Meek et aL, 1989; 
Navia et aL, 1989). 
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In the latently infected cell, the HIV provirus DNA is not expressed but is 
replicated as DNA by the host cell DNA polymerase, and is transmitted to progeny cells 
by cell division. Many HIV positive patients during the asymptomatic period of HIV-
infection are latently infected. Without the expression or surface adherence of HIV 
proteins, such latently infected cells are not attacked by the immune system (Connor et 
al., 1997). 
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Figure 1.4: Life cycle of HIV-1. (Adapted from Georgiev and Mcgowan, 1993). Steps in 
viral replication: (1) Attachment. (2) Fusion and penetration. (3) Uncoating. (4) Reverse 
transcription of single strand RNA. (5) DNA synthesis of second strand. (6) Migration to 
nucleus and integration. (7) Viral transcription. (8) Translation. (9) Post-translational 
modification by protease (10) RNA packaging and virion assembly (11) Release of vims. 
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1.2.5 Three Essential Enzymes for HIV-1 Replication 
1.2.5.1 HIV-1 Reverse Transcriptase (HIV-1 RT) 
The enzyme reverse transcriptase is used by retroviruses to transcribe their single-
stranded RNA genome into single-stranded DNA and to subsequently construct a 
complementary strand of DNA, providing a DNA double helix capable of integration into 
host cell chromosomes. , 
Functional HIV-1 RT is a heterodimer containing subunits of 66 kDa (p66) and 
51 kDa (p51). p66 contains two domains, the N-terminal polymerase domain (440 
residues) and the C-terminal RNase H domain (120 residues), p51 is processed by 
proteolytic cleavage of p66 and corresponds to the polymerase domain of the p66 subunit 
(Litvak, 1996). 
Amino acid sequences ^^^KLVGKL(X)i6KLLR^^^ of HIV-RT are conserved in 
several polymerases. It was identified as an element of nucleic acid binding apparatus. It 
forms part of helix-turn-helix lying within the thumb region. Molecular modeling studies 
suggested that the motif act as a kind of ‘helix damp，in the p66 and p51 subunits 
(Hermann etal., 1994). 
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1.2.5.2 HIV-1 Integrase (HIV-1 IN) 
HIV-1 integrase (HIV-1 IN) is a 31 kDa protein produced from the C-terminal 
portion of the Pol gene product (Andrake and Skalka, 1996). It is responsible for the 
integration of proviral DNA into the host genome, which is essential for HIV replication. 
The HIV-1 m , therefore, remains a promising potential target for new anti-AHDS 
therapeutics. 
The full length of HIV-1 JN (288 amino acids) has three domains; the catalytic 
core, the C-terminal, and the N-terminal domains. Although all three domains are 
required for integration, it is thought that the catalytic core domain (residues 50-212) 
‘ contains the active site responsible for catalysis of all the reactions of 
integration/disintegration (Andrake and Skalka, 1996). The C-terminal domain confers 
the capacity to bind both viral and host DNA. The structures of the catalytic core and C-
terminal domains have been determined separately (Roth et aL, 1989). The structure and 
function of the N-terminal domain are presently unknown, but it contains a His2Cys2 
zinc-binding motif suggesting an interaction with nucleic acid (Engelman et al., 1991). 
The structure of the catalytic core domain (CCD) of HIV-1 JN consists of a central five-
stranded B sheet with six surrounding helices. Three amino acids in the CCD are highly 
conserved in retroviral integrases (Khan et al., 1991). Mutation of these residues 
generally leads to a loss of all catalytic activities of these proteins, and they are therefore 
thought to be essential components of the integrase active site (Zhao et al., 1997). 
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1.2.5.3 HIV-1 Protease (HIV-1 PR) 
The proteins that comprise the HIV are produced in the form of long 
"polyproteins." These polyproteins must be cleaved to yield the active protein 
components of the mature virus. The HIV-1 PR is an aspartic protease that functions to 
cleave the nascent polyproteins during viral replication (Meek et al., 1989; Navia et al., 
1989). The protein precursor, Gag and Gag-Pol must be cleaved by the protease at 9 
specific points in order to produce functional proteins. The gag precursor will eventually 
give rise to structural proteins and pol precursor will give rise to enzymes such as reverse 
transcriptase, integrase, and protease. Thus, an HIV specific protease is necessary for the 
HIV to make more functional viruses (Meek et al., 1989; Navia et al., 1989). 
HIV-1 PR is a dimeric protein with two monomer subunits. Each monomer 
subunit contains two-twisted beta sheets and a small alpha helix. Each monomer consists 
oftwo identical polypeptides of 99 amino acids, having an N-terminal Pro and C-terminal 
Phe (Navia et aL, 1989). The active site is stabilized by hydrogen bonds involving the 
threonine residue at position 26, which forms rigid network referred to as a 'fireman's 
grip’ (Wlodawer etaL, 1989). 
The proposed cleavage sites for HIV-1 PR are of the sequence Ser(Thr)-Xaa-Yaa-
Phe(Tyr)-Pro. It is unique in that it can cleave between a phenylalanine or tyrosine and 
proline. This cleavage is unique to retroviral protease because no other mammalian 
endopeptidase is found to cleave at Tyr/Phe-Pro bonds (Pearl and Taylor, 1987). 
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1.2.6 The Different Stages of HIV Infection -
AEDS represents the final stage of a continuous, progressive pathogenic process, 
beginning with primary infection with HIV. There is a chronic phase that is usually 
asymptomatic. Then, the progression will lead to severe symptoms and, ultimately, 
profound immunodeficiency and opportunistic infections and cancers. 
HIV progression can generally be broken down into four distinct stages; primary 
infection (seroconversion), clinically asymptomatic stage, symptomatic HIV infection, 
and progression from HIV to AJDS (Lears and Alwood, 2000). 
“ The primary infection lasts for a few weeks and is often accompanied by a short 
flu-like illness which occurs just after infection. This flu-like illness is sometimes 
referred to as seroconversion illness. Some people have serious symptoms enough to 
consult a doctor, but the diagnosis is frequently mistaken for general flu. Even if an HIV 
antibody test is done at this time, it may not yet be positive. During this stage there is a 
large amount of HIV in the peripheral blood and the immune system begins to respond to 
the virus by producing HIV antibody and cytotoxic lymphocytes (Schacker et al., 1996). 
The asymptomatic stage lasts for an average of ten years and is free from any 
symptoms, although there may be swollen glands. The level of HIV in the peripheral 
blood drops to very low levels but people remain infectious and HIV antibodies are 
detectable in the blood. Research has shown that HIV is not dormant during this stage, 
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but is very active in the lymph nodes. Large amounts of T helper cells are infected and a 
large amount of virus is produced (Lears and Alwood, 2000). 
The symptomatic stage refers to the condition at which the immune system loses 
the struggle to contain HIV. This is for three main reasons: (1) the lymph nodes and 
tissues become damaged or 'burnt out' because of the years of activity; (2) HIV mutates 
and becomes more pathogenic leading to more T helper cell destruction; and (3) the body 
fails to keep up with replacing the T helper cells that are lost (Connor et al., 1997). 
As the immune system fails, a variety of symptom begins to develop. Initially 
many of the symptoms are mild, but as the immune system deteriorates the symptoms 
“ worsen. Symptomatic HIV infection is mainly caused by the emergence of opportunistic 
infections and cancers that normally the immune system would prevent (Lears and 
Alwood, 2000). Table 1.3 shows the common symptoms at the symptomatic stage of 
HIV-1 infection. 
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Table 1.2: Symptomatic HIV infection is often characterized by multi-system disease. 
(Adapted from (Lears and Alwood, 2000)) 
System Examples of Infection/Cancer 
Respiratory system Pneumocystis Carinii Pneumonia (PCP) 
Tuberculosis (TB) 
Kaposi's Sarcoma (KS) 
Gastro-intestinal system Cryptosporidiosis 
Candida 
Cytomegolavirus ( C M V ) . 
Isosporiasis 
Kaposi's Sarcoma 
Central/peripheral Nervous system Cytomegolavirus 
_  Toxoplasmosis 
Cryptococcosis 
Non Hodgkin's lymphoma 
Varicella Zoster 
Herpes simplex 




The final stage of HIV-1 infection is clinically defined as AH)S. It is 
characterized by a variety of indicator conditions as well as CD4 cell counts below 
200/mm3 define an AE)S case. When the CD4 cell count drops below 50/mm3, a patient 
has advanced infection and a limited life expectancy (Ho et al., 1995). Disseminated 
Mycobacterium avium complex and disseminated cytomegalovirus (CMV) may occur 
during this stage. Virtually all patients who die of HIV complications are in this stage 
(Lears and Alwood, 2000). 
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Figure 1.5: A graph shows the 4 stages of HIV infection. 
http://www.tthhivclinic.com/overview_home.htm 
1.3 AIDS therapy 
22 
1.3.1 Drugs Approved by US Food and Drug Administration (FDA) 
Antiretroviral drugs for the treatment of HIV diseases have been approved by the 
Food and Drugs Administration (FDA) in 1987. Theoretically, the drugs approved were 
based on the antiviral action on the multiple steps in the replication of HIV. 
Nucleoside analogues targeted on HIV reverse transcriptase were the first group 
of compounds shown to be effective against HIV infections and approved by FDA. 
Azidothymidine (AZT) was the first nucleoside analogues shown to have potent anti-HIV 
activity. AZT enters cells by passive diffusion, and appears to be phosphorylated by the 
same enzymes that convert thymidine (dT) to dT-5'-TP. AZT-triphosphate (AZT-TP) is 
the active species, acting as a chain terminating substrate for HIV reverse transcriptase 
(HIV-RT) during either first or second strand DNA synthesis (Hirsch and D'Aquila, 
1993). Four other drugs in this class have also been approved - didanosine (ddI), 
zalcitabine (ddC), stavudine (D4T) and lamivudine (3TC); were nucleoside analogs. All 
four of these drugs and other nucleoside analogs are believed to have a similar 
mechanism of HIV inhibition, in which the nucleosides are progressively phosphorylated 
to a 5'-triphosphate, which then acts as a chain terminator in a reverse transcriptase (RT) 
reaction (Kinloch-Loes et al., 1995). The major limitations of nucleoside analogs include 
their toxicity and susceptibility to viral resistance. Toxic side effects vary from 
compound to compound: anemia and/or neutropenia are frequently seen with AZT; 
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neutropenia and peripheral neuropathy with 3TC; peripheral neuropathy with ddC, D4T 
and ddI; and acute pancreatitis with ddI (Hirsch and D'Aquila, 1993). 
Another classes of inhibitors also targeted on HIV reverse transcriptase are non-
nucleoside reverse-transcriptase inhibitors. Nevirapine and Delavirdine are two the drugs 
belong to the classes and have been approved by FDA in US. They bind to a hydrophobic 
pocket in reverse transcriptase when transcriptase is complexed to DNA. This binding 
does not interfere with DNA synthesis (Spence et al, 1995). 
The HIV protease is another therapeutic category in which a drug has been 
approved for treatment of HIV infection. The first inhibitor of HIV protease approved by 
“ FDA for clinical usage was saquinavir, then ritonavir and indinavir. These drugs inhibitor 
HIV protease to cleave the Gag-Pol polyprotein precursor, which to produce viral reverse 
transcriptase, integrase, protease, matrix, capsid and nucleocapsid that is crucial for viral 
replication (Bartlett, 1996). 
Because of the problems related to drug toxicity and viral resistance, combination 
drug therapy for HIV treatment was used. The first successful use of combination drug 
therapy was approved by FDA by the use of ddC in combination with AZT for adult 
patients with advanced HIV infection who were continuing to show signs of clinical or 
immunological deterioration. In a double-blind study, 302 patients with a history of 
extensive AZT treatment were tested. They were given one of three therapeutic 
regiments: AZT and ddC; AZT, saquinavir; AZT, ddC and saquinavir. After 24 weeks, 
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the patients group of using AZT, ddC and saquinavir combination drug therapy were 
tested for more effective in increasing CD4 T cell count (40 to 50 cell increase) and 
decreasing viral load (0.5 log decline in HIV RNA) than another two regiments. Thus, the 
current recommendation for combination drug therapy was using two nucleoside 
inhibitors and one protease inhibitor (Chopra and Tyring, 1997). Apart from combination 
of AZT, ddC and saquinavir, combination with 3TC and AZT, including non-nucleoside 
reverse transcriptase inhibitor and various protease inhibitors were used and results also 
showed that HIV RNA levels reduced dramatically with some 3TC combination 
regiments (Perry and Faulds, 1997). 
Table 1.3: Antiviral HIV drugs approved by the FDA. 
^ u g Name Brand Name Inhibitors 
Zidovudine (AZT, ZDU) Retrovir® Reverse Transcriptase (nucleotide analogs) 
C)idanosine (ddI) Videx® Reverse Transcriptase (nucleotide analogs) 
2alcitabine (ddC) Hivid® Reverse Transcriptase (nucleotide analogs) 
Stavudine (d4T) Zerit® Reverse Transcriptase (nucleotide analogs) 
Lamivudine (3TC) Epivir® Reverse Transcriptase (nucleotide analogs) 
Nevirapine Viramune® Reverse Transcriptase (non-nucleotide analogs) 
^elavirdine Rescriptor® Reverse Transcriptase (non-nucleotide analogs) 
Saquinavir (hard gelatin capsule) Invirase™ Protease 
Ritonavir Norvir™ Protease 
Indinavir Crixivan® Protease 
Saquinavir(softgeiatincapsuie) FortovaseTM Protease 
(Chopra etaL, 1997;Wong, 1998) 
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1.3.2 Vaccine 
The first HIV vaccine trial was conducted in 1988. Since then, a total of 49 
clinical trials of 26 different vaccine candidates had been studied through National 
Institute of Allergy and Infectious Diseases (NIADD's) AH)S Vaccine Evaluation Group 
(AVEG). HIV vaccine research has progressed from an early focus on HIV surface 
antigens, particularly the envelope proteins and the role of neutralizing antibodies to 
cytotoxic T cells (CTLs) in HIV immunity. Many novel approaches to elicit anti-HW 
neutralizing antibodies and CTLs are now under investigation (Gotch et al., 1999). 
However, there are many challenges in developing AEDS vaccines. (1) HIV 
‘ continually undergoes mutation and recombination, and multiple HIV genetic subtypes 
were found which means that a vaccine need to act against more than one strains of virus. 
(2) The safety in using live attenuate virus vaccine was concerned. (3) The correlation of 
antibodies to the protection against HIV are still unknown. The presence of antibodies 
may not be the crucial factor. It might be the activated immune cells or a combination of 
immune responses. (4) Researchers lack an ideal animal model for AffiS vaccine testing 
(Johnston, 1997). 
Different candidate vaccines have been designed and developed. They include 
live attenuated virus, peptide vaccine, recombinant vector vaccine and DNA-based 
vaccines. Peptide vaccine is based on the use of entire peptide or a short sequence of 
amino acid from an HIV protein as immunogens. Surface protein gpl60 was already used 
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to elicit the immune response (Fleury et al., 1996). 'Another candidate vaccine, 
recombinant canarypox virus vector, expressing the HIV-lMN env followed by booster 
immunizations with a soluble recombinant envelope gpl60MN/LAi, was used to induce 
HIV-1 envelope specific cytotoxic T lymphocyte (Fleury et al., 1996). The development 
of DNA-based vaccine has shown the ability of expressing antigen in vivo. In a study of 
DNA vaccination on human, a group of patient (20) with HIV-1 seropositive was injected 
with three dosage of envelope vaccine (30，100, 300^ig). For the group who injected by 
100|Lig does showed an increase in antibody response to envelop proteins and peptides 
(Bagarazzi etaL, 1998). 
1.3.3 Chemokine Receptor Inhibitor 
Over the past few years, there is increasing evidence that the genes encoding these 
receptors can be located between individuals. This led to studies of how such gene 
polymorphisms affect the susceptibility of HIV infection (Rowland, 1999; Vaddi et al., 
1997). 
T22 ([Tyr,Lys]-polyphemusin II) is a synthetic peptide with 18 amino acid 
residues and an analogue of polyhemusin II isolated from the hemocyte debris of 
American horseshoe crabs shown to prevent chemokine receptor exhibiting HIV-1 
coreceptor properties. It was found that T-tropic HIV-1 infection to the cells expressing 
CXCR4 and CD4 was inhibited (Murakami et aL, 1997). Another small molecule 
ALX40-4C, a polypeptide of 9 arginine residues stabilized by terminal protection and 
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inclusion of D amino acids, showed inhibitory activity on infection by T-tropic virus 
strains before reverse transcription with an IC50 of 3nM (Doranz et al., 1997). Antibodies 
that bind specifically to the surface of CCR5 were found. 
Antibodies were isolated from two individuals homozygous for 32 base pair 
deletion in the gene coding for CCR5 when compared the serum from these individuals 
and those from CCR5+" individuals. Binding of the antibodies to CCR5 receptor was 
found to inhibit infection of primary isolates of HIV-1 (Ditzel et al., 1998). 
1.3.4 Antisense Oligonucleotides Therapy 
• The recent clinical trials using antisense oligonucleotide therapy for viral 
infections have provided a new dimension in drug therapy. Antisense oligonucleotides 
are short chains of nucleic acids, usually 10 to 30 residues long, and are intermediate in 
size compared with smaller-size conventional drugs and the much larger therapeutic 
polypeptides (Askari and McDonnell, 1996). 
HIV replication in both acutely and chronically infected human cells can be inhibited 
by unmodified and modified antisense oligonucleotides. Another attempts to block HIV 
integration into the human genome have been partially successful (Askari and 
McDonnell, 1996). 
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Recently, the development of oligonucleotides with therapeutic value using the 
technique of SELEX (Systematic Evolution of Ligands by EXponential enrichment) has 
increased to generate compounds with high-affinity to biological target molecules (Tuerk 
and Gold, 1990). In 1993’ Tuerk and Waugh reported to use the SELEX to obtain high-
affinity RNA ligands against the reverse transcriptase and the Rev and Tat proteins of 
HIV-1 (Tuerk and Waugh, 1993). These descriptions serve as the starting point for the 
ultimate development of compounds intended to alter the course of HIV-1 infection. 
1.3.5 Traditional Chinese Medicine (TCM) 
Traditional Chinese medicine (TCM) has been extensively used to prevent and 
.• cure many diseases that have inflicted humans for over a millennium. In particular, the 
merits of low toxicity and rare complications have subsequently led to considerable 
attention in various fields. Among pertinent investigations include the analysis of active 
ingredients ancV or major components of the medicine, treatment of diseases and the 
search for alternative drugs (Lu, 1995). 
The philosophy of Chinese medicine emphasizes treatments, which enhance the 
body's natural immunities so that the body is more effectively prepared to fight for the 
disease. Herbs used in China for immunomodulation can be classified into three 
categories. The first group of herbs is to enhance the immune system. The second group 
is to inhibit the immune system and the third one has a non-specific adaptogenic effect 
(Lu, 1995). 
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The scientific basis for using Chinese herbs against HIV infection originates from 
several sources of laboratory investigations. In 1988，Chang and Yeung's paper described 
11 species with anti HIV effects in the H9 cell line. These antiretroviral species include 
arctium, epimedium, lonicera, viola, andrographis, coptis, prunella, and lithospermum 
(Chang and Yeung, 1988). 
Crude plant extracts were also found to be effective on multiple stages of HIV 
replication. For the study of inhibition on HIV-l reverse transcriptase, extracts of forty 
one folk medicine used in Egypt were screened and six of them showed significant 
inhibitory activity with an IC50 < 50|ig/ml. They included extracts from Phyllanthus 
amblica, Quercus pedunculata, Rumexcypruis, Terminalia bellerica, Terminalia chebula 
and Terminalia horrida. Phyllanthus emblica showed potent inhibitory activity to HIV-1 
reverse transcriptase with an IC50 of 9|ig/ml and lO^ig/ml in methanol and water extracts 
respectively (El Mekkawy et aL, 1995). In another study of 35 Chinese medicines plant 
extracts on HIV-1 reverse transcriptase, 14 of them was found to reduce reverse 
transcriptase activity by greater than 30%. Tan et aL (1990) have screened 100 methanol 
extracts of plants and it is found that about 15% had their ability to inhibit reverse 
transcriptase. In 1997，Collins and his colleague detected 19 aqueous extracts and 2 of 
them contained potent reverse transcriptase, stem of Chrysanthemum morifolium (n)50 of 
16.9^ig/ml) and Prunella vulgaris (©50 of 26.0^ig/ml). 
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Several studies have been carried out and showed the strong inhibition on HIV-1 
protease. In 1995, Kusumoto et al. examined the plant extracts traditionally used in India, 
and the aqueous extracts of Areca catechu was found to be the most potent inhibitor with 
IC50 12|ig/ml (Kusumoto et aL, 1995). In 1996，Xu et al screened 25 traditional 
medicines and 5 of them found to be effective at concentration 25^ig/ml. They included 
Belamcanda chinensis, Magnolicfargesii, Paeonia sujfruitcosa, Phellodendron amurense 
and Terminalia chebula (Xu et al., 1996). In another study of 231 crude extracts of New 
Zealand plants, it was found that 16 of them showed more than 30% inhibition at 
concentration of 50^ig/ml (Wan et al, 1996). Screening of aqueous and methanol extracts 
of 39 Pananmanian medicinal plants showed that 7 out of them were found to be 
moderate inhibitors. They includes Aegiphila anomala, Cordia spinescens, Erythroxylum 
citrifolium, Lindackeria laurina, Serjania mexicana, Waltheria indica and Xylopia 
frutescens (Matsuse et al, 1999). 
For plant natural products against HIV-1 integrase, (-)-arctigenin was showed to 
be effective. (-)-Arctigenin is a naturally occurring lignanolide that has been shown to 
inhibit HFV-1 in tissue culture systems (Eich et al., 1996). In another study, plant proteins 
MAP30 {Momordica anti-HIV protein of 30kDa) and GAP30 {Gelonium anti-HIV 
protein of 31 kDa) were isolated and identified as anti-HIV integrase plant protein (Lee-
Huang et al., 1995). In 1998’ a study of an ethyl acetate extract of the leaves of Acer 
okamotoanum was found out a new acylated flavonol glycoside, quercetin 3-0-(2' ,6 '-0-
digalloyl)-p-D-galactopyranoside and exhibited with IC50 of 18.1nM against HIV-1 
integrase (Kim et al, 1998). 
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1.4 Objective of My Project 
One of the objectives of my project is to isolate active principle from Chinese 
medical herbs on inhibition of HIV-1 protease. Another objective is to select RNA 
aptamers for high affinity ligand to HIV-1 protease using the technique of Systematic 
Evolution of Ligands by EXponential emrichment (SELEX). 
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CHAPTER 2 
SCREEN^G OF TRADITIONAL CHEESE MEDICWAL PLANTS FOR HIV-1 
PROTEASE DSfHffimON 
2.1 Introduction 
Traditional Chinese medicinal herbs have been shown to be effective in inhibiting 
the growth of HIV in vitro. Further analysis of these medicinal herbs in various enzyme 
assays demonstrated that some of the extracts exerted their effects at different stages in 
HIV-1 replication (Lu, 1995). On of the target is the HIV-1 protease (HIV-1 PR). 
Chang and Yeung were the first investigators to examine ancient Chinese folklore 
known for anti-HIV activities. The water extracts were tested for inhibitory activity 
against HIV in the H9 cell line. Eleven of twenty-seven extracts were found to be active 
(Chang and Yeung, 1988). 
In 1995，Kusumoto et. al. screened plants extracts traditionally used in India and 
showed that some of them inhibited HIV-1 PR at the concentration 200p.g/ml, such as the 
aqueous extracts of Aeca catechu, Terminalia arhjuca, Eugenia jambolana, Ficus 
reliogiosa, Litsea sebifera, Myristicafragrans, Pogfostemon heynaenus, Rhus acuminata 
and Terminalia chebula as well as methanol extracts of Aceca catechu, Eugenia 
jambolana, Terminalia arjuna, Cassiafistula, Mimusops dlengi and Terminalia chebula 
(Kusumoto etal., 1995). 
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In 1996，Xu et al. reported that extracts from Anemarrhena asphoodeloides, 
Epimedium sagittatum, Oldenlandia diffusa, Phellodendron amurense, Sophora japonica 
and Taraxacum mongolicum showed strong anti-HIV-1 PR activity (Xu et al., 1996). In 
another study, Wan et aL (1996) found that 16 out of 231 ethanol/aqueous New Zealand 
plants extracts exhibit more than 30% inhibitory against HIV-1 PR at the concentration 
50|Llg/ml, such as Elaeoaarpus hookerianus, Caainia letophylla, Pernettya macrostigma 
and Pseudotsuga menziesii (Wan et aL, 1996). 
In 1999，Matususe et al. examined 39 Pananmanian medicinal plants aqueous and 
methanol extracts. Seven out of 39 plants were found to be moderate inhibitors of HFV-1 
PR (IC50: 43-lOO^ig/ml). They include Aegiphila anomala, Cordia spinescens, 
Erythroxylum citrifolium, Lindackeria laurina, Serjania mexicana, Waltheria indica and 
Xylopia frutescens (Matsuse etaL, 1999). 
Using similar approach, we have examined and extend the screening of herbal 
extracts for HIV-1 PR inhibitory effects. 
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2.2 Materials and Methods 
2.2.1 Materials 
Thirty-one medicinal herbs used in this project were bought from local herb shop 
(Tong Ren Tong). 
Ampicillin, chloramphenical, glycerol, isopropylthio-p-D-galactoside (IPTG), 
phenylmethyl-sulfonyl fluoride (PMSF), Nonidet-P40, imidazole, dithiothretiol (DTT), 
magnesium chloride (MgCl2), sodium chloride (NaCl), bovine serum albumin (BSA), 
HIV-1 protease synthetic peptide substrate (Acetyl-Ser-Gln-Asn-Tyr-Pro-Val-Val-
amide), N-terminal cleavage fragment of HIV-1 protease synthetic peptide substrate 
(Acetyl-Ser-Gln-Asn-Tyr), ethyl glycol, and 2-(N-morpholino)ethanesulfonic acid (MES) 
were purchased from Sigma. 
Dialyzing membrane with 3500 MWCO was obtained from Spectrum. 
DEAE Sepharose CL-6B, and Mono-S HR 5/5 cation exchange column were 
obtained from Amersham Pharmacia Biotech. 
Disodium ethylenediaminetetra-acetate-2H2O (EDTA), and DNase I were 
purchased from Life Technologies. 
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Methanol (Anal grade), acetic acid, and sodium acetate were obtained from BDH. 
Centriprep-3 was purchased from Centricon. 
Mini-Protean II electrophoretic system, acrylamide, bis-acrylamide, ammonium 
persulfate, N',N',N' ,N'-termethylethylenediamine (TEMED), SDS-PAGE Prestained 
marker (MW range 7.4kDa to 203kDa), Econo-column, Bradford reagent, and microtiter 
plate reader (Model 3550) were purchased from Bio-Rad. 
Fluorogenic HIV protease substrate (Arg-Glu(EDANS)-Ser-Gln-Asn-Tyr-Pro-Ee-
Val-Gln-Lys(DABCYL)-Arg) was obtained from Molecular Probe. 
Ninety-six well sterilized plate was obtained from Corning. 
Spectrofluorometer Perkin Elmen LS50B. HPLC system which includes 600S 
controller, 486 tunable absorbance detector and 717 autosampler was obtained from 
Waters. 
2.2.2 Extraction Methods 
2.2.2.1 Aqueous Extraction 
The dried herb (2g) was cut into small pieces and soaked in 10ml of double 
distilled water. The herb was then boiled in water under reflux for 2 hours. After filtration 
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through Whatman Paper No. 1 to remove insoluble debris, the water extract was dialyzed 
against 2 litres of double distilled water at 4 � C overnight (-16 hours). The dialyzate was 
then frozen and lyophilized. The dried extracts were stored at -20�C until assay (Tabba et 
al., 1989). 
2.2.2.2 Methanol Extraction 
The dried herb (2g) was cut into small pieces and soaked in 10ml of absolute 
methanol (Anal grade) for 24 hours at 4°C. The extract was then filtered through 
Whatman Paper No. 1 to remove the insoluble material. Afterward, the filtrate was dried 
by SpeedVac system (Savant UVS400A) and the dried extract was kept at 4 � C until assay 
(Tabba etal, 1989). 
2.2.3 Preparation of Recombinant HIV-1 Protease 
2.2.3.1 Selection ofAppropriate Clone 
The recombinant HIV-1 PR expression vector cDNA was a generous gift from 
Dr. Jordan J. N. Tang at Oklahoma Medical Research Foundation. The recombinant HIV-
1 PR cDNA was cloned into the expression vector, pET3b (Novagen) and propagated in 
E. Coli BL21(DE3)pLysS. The transformed bacterial stocks were stored in 20% glycerol 
at -80�C. Screening of bacterial colonies was done by streaking the frozen bacterial stock 
on LB agar plate with 50p^g/ml ampicillin and 34p,g/ml chloramphenical. After an 
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overnight incubation at 37°C, bacterial colonies were picked out (Lin et al., 1994). Each 
bacterial colony was grown in 2ml LB broth with 50^g/ml ampicillin and 34^ig/ml 
chloramphenical for 3 hours at 37°C with orbital shaking at 240 rpm. Afterward, 0.5ml of 
bacterial culture was taken and kept for SDS-PAGE analysis and 0.5ml for preparing 
20% glycerol stock. The induction of expression of recombinant HIV-1 PR was then 
initiated by the addition of 0.4 mM IPTG into the remaining bacterial culture and grow 
for 3 hours at 37°C with orbital shaking at 240 rpm. 
2.2.3.2 Large-scale Expression ofRecombinant HIV-1 Protease 
The clone that was demonstrated to express HIV-1 protease as indicated by SDS-
PAGE analysis was used for a large-scale culture. The streaking of the 20% glycerol 
bacterial stock of that clone was added into 2ml LB broth with 5O|0,g/ml ampicillin and 
34p,g/ml chloramphenical and then grow for overnight at 37°C with orbital shaking at 
240 rpm. After an overnight culture, 200^il of the bacterial broth was added into 200ml 
LB broth with 50^ig/ml ampicillin and 34|Lig/ml chloramphenical, and grown for 3 hours 
at 37°C with orbital shaking at 340 rpm. An amount of 1ml bacterial culture was stored 
after the incubation. 0.4mM of IPTG was added into the remaining bacterial culture and 
incubated for 3 hours at 37°C with orbital shaking at 340 rpm. Then, the bacterial was 
collected by centrifugation at 3000 rpm for 15 minutes at 4°C. The supernatant was 
discarded and the pellet was stored at -20�C for chromatographic purification (Lin et al., 
1994). 
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2.2.3.3 Purification of Recombinant HIV-1 Protease by DEAE Sepharose CL-6B 
Chromatography 
Recombinant HIV-1 PR was prepared and purified according to the method 
described in Lin et al. (1994) using anion-exchange chromatography on DEAE Sepharose 
CL-6B. An amount of approximately 5g of the bacterial cell pellet was thaw and 
suspended in 10ml of ice-cold Buffer A (lOmM Tris-Cl, pH 8.0’ 2mM EDTA, and lmM 
PMSF) for 20 minutes in an ice-bath. Nonidet-P40 was then added into the solution to 
0.1% (v/v). The cell suspension was gently stirred for 10 minutes, followed by the 
addition of MgCl2 and DNase I to a final concentration of lOmM and 4U/ml respectively. 
The cell mixture was then sonicated until the viscosity of the mixture decreased. The cell 
homogenate was centrifuged at 8000 rpm for 10 minutes at 4°C and the resulting pellet 
was resuspended into 100ml of ice-cold Buffer A containing l%(v/v) Triton X-100. After 
centrifugation at 8000 rpm at 4°C for 10 minutes, the supernatant was discarded and the 
pellet was dissolved into 10ml ice-cold Buffer B (lOmM Tris-Cl, pH 7.5’ 8M urea, and 
lOmM DTT). After removing the un-dissolved material by centrifugation at 8000 rpm for 
15 minutes at 4�C，the protein solution was then applied to DEAE Sepharose CL-6B 
anion exchange column (2.2 x 9 cm Bio-Rad Econo-column), which was pre-equilibrated 
at 4°C with Buffer B. The column was eluted with Buffer B at a flow rate of lml/min and 
1ml per fraction was collected. The chromatography was monitored at UV280nm. The 
HIV-1 PR that was eluted at the breakthrough peak was collected. The whole 
chromatographic procedure was done at 4°C (Lin et al., 1994). 
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2.2.3.4 Purification ofRecombinant HIV-1 Protease by Mono-S Cation Chromatography 
The recombinant HIV-1 PR enriched from the DEAE Sepharose CL-6B 
chromatography was further purified by cation-exchange on Mono-S column 
(Pharmacia). An amount of lOmg/ml of MES was added into the DEAE Sepharose CL-
6B purified protease solution and to adjust the pH to 6 with 2M acetic acid. Then the 
sample was applied into 1ml Mono-S column, pre-equilibrated with starting buffer 
(50mM Tris-Cl, pH 6.5 containing lmM EDTA and lmM DTT). The Mono-S column 
was connected to HPLC (Waters) and eluted at lml/min of a gradient profile showed 
below (Rittenhouse etal., 1990). 
‘ Time Starting Buffer (50mM Tris-Cl, pH 6.5 Eluting Buffer ( lM NaCl 
(minutes) containing lmM EDTA and lmM DTT) in nanopure water) 
0 — m 0 
— 5 - 100 0 
一 17 - 0 100 
一 30 — 0 100 
— 3 5 - 100 0 — 
— 4 0 100 0 
2.23.5 Refolding ofPurified Recombinant HIV-1 Protease 
The purified recombinant HIV-1 PR, after two chromatographic steps, was 
dialyzed against 4 L solution containing lmM DTT, 1% (v/v) glycerol and lOmM sodium 
acetate (pH3.5) at 4°C for 4 hours. The solution was then centrifuged at 10000g for 20 
minutes. The pH of the supernatant was adjusted to 4.4 with the addition of 100mM 
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sodium acetate (pH 4.4) containing lM NaCl. This solution was left standing at room 
temperature for 10 minutes, and centrifuged again for 10 minutes at 10000g. The 
supernatant was dialyzed against lOmM sodium acetate (pH 3.5) for 2 hours at 4°C. 
Finally, The recombinant HIV-1 PR solution was concentrated by Centriprep 3 
(Centricon) and stored in aliquots at -80°C (Lin et al., 1994). 
2.2.3.6 Protein Concentration Determination 
The protein concentration of the purified recombinant HIV-1 PR was determined 
by Bradford method (1976) (Bradford, 1976) and bovine serum albumin (BSA) was used 
as protein standard. 
2.2.3.7Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE was performed according to the method of Laemmli (1970). The gel 
was casted according to the instruction manual in the Bio-Rad mini-Protean II system. 
The SDS-Polyacrylamide gel used consisted of 15% separating gel and 5% stacking gel. 
The protein fractions were denatured in 25jji of 4 x loading buffer (200mM Tris-Cl, pH 
6.8，400mM DTT, 8% SDS, 0.8% bromophenol blue, and 40% glycerol), 75|il of double 
distilled water was added in order to dilute the loading buffer to 1 x fold. The samples 
were boiled for 10 minutes, and then centrifuged at 13,000 rpm for 5 minutes in order to 
remove the debris. About lO i^l of protein samples was loaded into each well. Five i^l of 
prestained SDS-PAGE marker was loaded as the protein molecular size marker. 
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Electrophoresis was run at constant voltage 120V in a running buffer containing 25mM 
Tris, 250mM glycine (pH 8.3), and 0.1% SDS. After electrophoresis, the gel was stained 
with Coomassive-blue (0.25g Coomassive Brilliant Blue R250 was dissolved in 90ml of 
methanol:water (1:1 v/v) and 10ml acetic acid). 
2.2.4 Characterization of HIV-1 Protease 
2.2.4.1 HIV-1 PR Fluorometric Assays 
The fluorometric assay was carried out with an HFV-1 PR fluorogenic substrate 
(Arg - Glu (EDANS) - Ser - Gln - Asn - Tyr -Pro - Ile — Val - Gln - Lys (DABCYL)-
‘ Arg).The substrate was dissolved in DMSO to make a lmM stock. The stock fluorogenic 
substrate was diluted to lOOpJVl with the assay buffer (O.lM sodium acetate, lM NaCl, 
lmM EDTA, lmM DTT and lmg/ml BSA, pH 4.7). An aliquot (lO^il) of substrate and 
3.5^1 HIV PR solution (1.3^ig/^l) were added to the reaction mixture in an assay buffer in 
the presence or absence of tested extracts to make a final reaction volume of 100|ji. The 
mixture was incubated at ?>TC for 1 hour. A control reaction was performed under 
identical conditions, but without the addition of HFV-1 PR. pepstatin A ( _ M ) was used 
as positive control for an inhibition of HIV-1 protease. More than 90% of the enzyme 
activity was inhibited by pepstatin A under these conditions. After incubation, lOp.1 of 
5.5% trifluoroacetic acid (TFA) was added to stop the reaction. The fluorescence 
intensity was measured in a spectrofluorometer (Perkin Elmen LS50B) with an excitation 
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wavelength of 340nm and an emission wavelength of 490nm (Matayoshi et aL, 1990; Xu 
etaL, 1996). 
2.2.4.2 HIV-1 PR Assay by Reverse Phase HPLC Separation of Cleavage Products ofthe 
Synthetic Peptide Substrate 
The proteolytic activity of HIV-1 PR was further confirmed by using the synthetic 
peptide substrate (Acetyl-Ser-Gln-Asn-Tyr-Pro-Val-Val-amide) with procedures 
according to Wan et aL (1996). The products of cleavage (Acetyl-Ser-Gln-Asn-Tyr and 
Pro-Val-Val-amide) were separated by reverse-phase HPLC. The assay was performed in 
a volume of 60p,l containing 6|il substrate (lOO^iM), 15 i^l HIV-PR (1.3^ig/^il) and 10|il 
plant extract (200^ig/ml) in 50mM sodium acetate buffer, pH 5.5. The reaction was 
carried out for 2 hours at 37�C and was terminated by adding 10 i^l 5.5% TFA. The 
supernatant obtained by centrifuging at 12,000 rpm for 5 min was then analyzed by RP-
HPLC separation on a Cig Protein/peptide reverse phase column (Vydac Cis 218TP) 
employing a Waters HPLC system. The N-terminal digested peptide of the substrate was 
used for internal standard. 
The Vydac Cig reverse phase column was first pre-equilibrated with starting 
buffer (0.1% trifluoroacetic acid in nanopure water) at flow rate O.lml/min. An amount of 
50^1 of assay volume was loaded into the HPLC. The eluate was monitored at UV215nm 
at a flow rate of 0.6ml/min. 
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The column was eluted with a gradient according to the following table using 
eluting buffer containing 0.1% trifluoroacetic acid in 100% acetonitrile. 
Time (minutes) Flow rate Starting Buffer (0.1% Eluting Buffer (0.1% 
(ml/min) trifluoroacetic acid in trifluoroacetic acid in 100% 
nanopure water) acetonitrile) 
— 0.6 — m 0 — 
— 5 “ 0.6 100 0 
— 2 5 “ 0.6 _ 80 20 
— 35 “ 0.6 70 30 
— 40 0.6 0 100 
— 85 “ 0.6 0 100 
— 9 0 0.3 100 . 0 
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2.3 Results 
2.3.1 Functional Analysis of Recombinant HIV-1 PR Activity 
The HIV-1 PR cDNA was cloned into an expression vector pET3b and was 
transformed into E. coli BL21(DE3)pLysS. After three hours of IPTG induction, the 
recombinant HIV-1 PR was expressed as an 11-kDa protein in SDS-PAGE (Figure 2.1). 
A nearly homogenous preparation of recombinant HFV-1 PR was obtained after two 
consecutive chromatographic steps on DEAE Sepharose CL-6B column and Mono-S 
cation exchange column. 
Two HIV-1 PR assays, the fluorescence and the HPLC assays, were used to 
validate our screening of inhibitory activity. The fluorometric assay is based on the 
sequence-specific cleavage of a substrate (Arg-Glu(EDANS)-Ser-Gln-Asn-Tyr-Pro-Ue-
Val-Gln-Lys(DABCYL)-Arg) at Tyr-Pro bond. This substrate contains two covalently 
modified amino acid residues, an N-terminal fluorophore (EDANS) and a C-terminal 
quenching group (DABCYL). The cleavage of this peptide resulted in the release of 
DABCYL-linked peptide fragments giving an increase in fluorescence intensity 
(Matayoshi et aL, 1990). The assay of recombinant HIV-1 PR using the fluorometric 
method is shown in Fig. 2.2. The enzyme activities were concentration-dependent and 
were inhibited by pepstatin A, an aspartic protease inhibitor. 
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Figure 2.1: SDS-PAGE analysis of recombinant HIV-1 PR expression. Lane M: 
prestained protein standard marker; Lane 1: uninduced bacterial lysate; Lane 2: 
IPTG-induced bacterial lysate; Lane 3: inclusion body fraction of induced 
bacterial lysate; Lane 4: lysate after DEAE Sepharose CL-6B column 
chromatography. Lane 5: protein fraction after Mono-S column chromatography. 
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Figure 2.2: Fluorometric measurement of recombinant HIV protease activity. The 
concentration of fluorogenic substrate used was lO^iM and the incubation time was one 
hour. The excitation wavelength was 360nm and emission wavelength was 460nm. Line 
a: no inhibitor was added. Line b: lO^M of pepstatin A was added to inhibit HFV-1 PR 
activity. 
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RP-HPLC assay is based on sequence-specific cleavage of the synthetic peptide 
with sequence acetyl-Ser-Gln-Asn-Tyr-Pro-Val-Val-amide. The sequence is the mimic of 
the retroviral polyprotein cleavage site (pl7/p24) of HIV-1 PR. RP-HPLC analysis 
confirmed that the cleavage is at the Tyr-Pro bond, as indicated by the appearance of the 
N-terminal cleavage product (Acetyl-Ser-Gln-Asn-Tyr) upon protease digestion. These 
results provide a firm validation of the specificity and selectivity in our assay methods 
towards HIV-1 PR (Fig. 2.3). 
2.3.2 Screening of Crude Extracts for Inhibition of HIV-1 PR Activity 
The fluorometric assay was used for the determination of HIV-1 PR inhibitory 
activities of the crude methanol and aqueous herbal extracts. The screening test was 
carried out at an extract concentration between 20 ^ig/ml and 200 ^ig/ml. At a 
concentration of 200 ^g/ml, 11 aqueous and methanol extracts were found to inhibit 
HIV-1 PR activity by more than 80%. Among them, the aqueous extracts of Prunella 
vulgaris and Scutellaria baicalensis showed the highest inhibitory activity (>90% 
inhibition). At a lower concentration (20 ^g/ml), the aqueous extracts of Paeonia 
sujfruticosa and Mentha haplocalyx caused more than 40% inhibition of HIV-1 PR 
activity (Table 2.1). 
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On the other hand, the methanol extracts of Woodwardia unigemmata, Paeonica 
sujfruticosa and Spatholobus suberectus also showed an inhibitory effect (>90% 
inhibition) at high concentration (200 |j.g/ml). At 20 ^ig/ml, the methanol extracts of 
Woodwardia unigemmata still caused about 40% inhibition (Table 2.2). To confirm the 
specific cleavage of substrate at Tyr-Pro residue, the methanol extract of W. unigemmata 
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Figure 2.3: Typical chromatograms of RP-HPLC assay. Six i^l of HIV-1 PR 
peptide substrate (100 ^M) and 15 ^1 of HIV-1 PR enzyme (1.3 pLg/yd) were 
incubated at 37°C for 2 hours. The reaction was stopped by adding 10 yd of 
5.5% TFA to a final concentration of 0.5%. (A) Hydrolysis of HIV-1 substrate 
(peak b) with HIV-1 PR. Peak a was identified as one of the cleavage peptides 
Acetyl-Ser-Gln-Asn-Tyr. (B) Complete inhibition of HIV-1 PR activity by 
pepstatin A pre-incubation. (C) Partial inhibition of HFV-1 PR activity by the 
methanol extract of W. unigemmata at concentration 200^ig/ml. 
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Table 2.1: Screening of the aqueous extracts from Chinese medicinal herbs on inhibition 
of HIV-1 protease activity. 
Name Used part % Inhibition % Inhibition 
(200^ig/ml extract) (20 ^ig/ml extract) 
Agastache rugosa ( 霍晉 ) Whole plant 7:8 土 0.8 5.5 + 1.2 
Andrographis panimlata (穿^>、蓮) Bark 57.2 土 0.2 1.5 土 0.3 
Arctium lappa ( 牛 _子 ) Fruit 6.9 土 0.6 2.7 土 0.5 
Areca catechu ( 檳榔 ) Seed 48.5 土 1.3 17.6± 0.5 
Baphicanthus cusia ( 板 藍 根 ） _^ Rhizome 28.7 土 4.1 13.7 土 2.3 
Chrysanthemum moriforlium ( j S ^ K ^ ) Capitulum 84.6土2.4 15.7土3.7 
Chrysanthemumindicum j^%^ ) Capitulum 7.9土2.2 3.4土0.7 
Clematidis chinerm^ 威 _ 仙 ） Root 60.4 土 1.1 24.7 土 1.1 
Coptis chinesis (黄蓮 Rhizome 17.7 土 8.8 2.3 土 0.4 
Fritillaria cirrhosa ( J11貝）、 Rhizome 1.7 土 1.3 3.4 土 0.3 
Ledebouriella divaricata ( 防風 ) Fungus 9.5 土 1.6 4.1 土 0.1 
Ligustmm lucidum (女貞^^ ) Fruit 35.6 :L4.0 6.8 ±_\2 
Lindera strychnifolia ( A S ) Root 39.8 土 1.4 10.8 土 0.8 
Lithospermum erythrorhizon (紅紫草 ) Root 43.2 土 10.8 0.9 土 0.1 
Lithospermum erythrorhizon ( i 匕 紫 萆 ) Seed 59.8 土 0.1 19.1 土 3.5 
Lonicera japnica (金銀花 ) Flower bud 24.6 土 2.4 6.1 土 4.3 
Mentha haplocalyx (薄荷） Whole plant 60.8 土 0.7 58.2 土 1.1 
Oldenlandia diffusa (白花蛇舌萆 ) Whole plant 80.8土1.8 2 2 . 6 ^ . 2 
Paeonca sujfmticosa (_^ (：丹皮） Root 59.7土2.7 55.8 ±_3.0 
Perillafrutescens (紫蘇葉） Leaf 58.1 土 1.6 14.2 土 5.9 
Polygonum multiflorum (1^¾".¾ ) Root 49.0±2.3 2.6±_\.6 
Prunella • 以 & £ ? ^ @ 枯 萆 ） Whole plant 93.5 土 3.2 17.4±0.5 
Pueraria lobata (富根） Root 75.5 土 1.5 38.4 土 1.0 
Radix Notoginseng ( B04：； ) Root \1.6±2.\ 8.6j^3.2 
Scutellaria baicalensis (黄宰) Root 91.1 土 0.5 37.7 土 0.1 
Senecio scandens ( ^ M 0 ) Whole plant 83.2 + 3.5 13.9 + 0.4 
Sophoriaflavescens ( ^ # ) Root 3.7 土 1.7 2.8 土 0.9 
Sophora tonkinesis (廣豆榷 ) Root 70.8 土 3.6 15.0± 0.3 
Spatholobus suberectus (雞血藤） Rhizome 42.0 4^3.8 17.6 +_3.6 
Viola yedoensis (紫花地丁丄 Whole plant 59.1 土 1.8 7.0 ^~0.1 
Woodwardia unigemmata (貝仲 ) Rhizome 59.1 土 8.2 9.0+ 1.6 
Concentration of the fluorogenic substrate was 10 \iM and the amount of enzyme used 
was 5 ^ig. Intensity of fluorescence was measured at an excitation wavelength of 340 nm 
and at an emission wavelength of 490 nm after incubation for 1 hour. Values are means 土 
S.E.M., n=3 
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Table 2.2: Screening of the methanol extracts from the Chinese medicinal herbs on 
inhibition ofHFV-l protease activity. 
Name Used part % Inhibition % Inhibition 
(200p^g/ml extract) (20M g^Zml extract) 
Agastache rugosa ( 霍 香 ) Whole plant 35.64 + 0.13 21.11 + 0.25 
Andrographis pani<Mata (穿<^、蓮) Bark 23.21 土 2.66 1.98 土 0.16 
4^ :"“爪/以厂尸《(牛—子） Fruit 15.63±7.02 3.12 + 0.02 
Areca catechu ( 檳鄉 ] Seed 46.22 土 0.22 21.90 土 0.32 
Baphicanthus cusia (板藍根） Rhizome 21.51 土 2.78 1.88 土 0.42 
Chrysanthemum moriforlium ( ^ ¢ 1 ¾ ) Capitulum 60.64土4.12 22.73土3.79 
Chrysanthemum indicum^%1Z) Capitulum 5.76土0.26 3.26土0.47 
a e m a t i d i s c h i n e f ^ 4 ^ ^ l h ) Root 17.42土9.51 9.55土3.41 
Coptis chinesis ( M M ) Rhizome 74.63 ± 9.92 20.23 + 7.48 
Fritillaria cirrhosa ( JI|貝） Rhizome 3.17 + 0.03 6.53 ± 0 . 5 7 
Ledebouriella divaricata ( | & ® ) Fungus 11.84 土 0.26 4.34 土 0.33 
Ligustrum lucidum ( ^ ^ J ? ) Fruit 84.40土7.35 18.85土2.83 
Linderastrychnifolia(SM) Root 84.09土0.42 3.96土0.72 
Lithospermum erythrorhizon (羊工紫草） Root 9.88 土 1.58 3.20 土 0.62 
Lithospermum erythrorhizon ( i匕紫萆> Seed 57.62 土 1.89 3.00 土 1.29 
Lonicerajapnica (金 1 |花 ) Flower bud 28.61 土 2.66 20.61 土 3.62 
Mentha haplocalyx (薄荷） . Whole plant 41.17 土 0.32 10.77 ± 0.51 
Oldenlandia diffusa (白花蛇舌草 ) Whole plant 29.89 土 2.13 2.28 ±1.39 
Paeonca sujfruticosa (_^1丹皮） Root 91.16 土 1.02 39.89 土 1.36 
Perillafrutescens ( ^ B K ) Leaf 50.74 + 6.16 3.06 + 0.13 
Polygonum multiflomm (倚苜島 ) Root 70.90 土 0.39 12.46 土 0.57 
Prunella vulgaris^^^^) Whole plant 32.70 土 3.49 25.44 土 4.27 
Pueraria lobata ( 富根 ) Root 32.49 土 0.33 10.87 土 0.12 
Radix Notoginseng (田“^ Root 78.30 土 7.00 23.14 土 6.01 
Scutellaria baicalensis ( M ^ ) Root 60.58 土 1.23 15.78 土 0.11 
Senecio scandens ( ^ S B ) Whole plant 81.63 + 3.43 13.56 + 2.97 
Sophoriaflavescens ( " ^ ) Root 7.27 土 2.33 2.39 土 1.03 
Sophora tonkinesis (廣豆稂） Root 27.59 土 10.11 11.43 土 3.22 
Spatholobus suberectus (雞血藤) Rhizome 97.19 土 3.18 29.54 土 1.29 
Viola yedoensis (紫花地丁‘ Whole plant 59.72 土 4.79 14.43 ± 0.56 
Woodwardia unigemmata ( W # ) Rhizome 91.96±6.48 39.41 + 8.42 
Concentration of the fluorogenic substrate was 10 )jJVI and the amount of enzyme used 
was 5 ^ig. Intensity of fluorescence was measured at an excitation wavelength of 340 nm 




Natural products such as flavonoids have previously been reported to have 
inhibitory effects on HIV-1 PR (Brinkworth et aL, 1992). More recently, Xu et aL (1996) 
examined the aqueous extracts of 75 herbs and showed that five of them exhibited 
effective inhibition at 25 |Xg/ml. Using a similar approach, we have examined both the 
aqueous and methanol extracts of thirty-one medicinal herbs. The results demonstrated 
that certain herbal extracts showed differential effective inhibition on HIV-1 PR activity. 
Five of the aqueous extracts elicited >80% inhibition of HIV-1 PR activity at 200 p.g/ml. 
Several extracts reported here {A. lappa, L japonica, W. unigemmata, V. yedonesis, S. 
scandens, A. paniculata, C. chinensis, P. vulgaris and L. erythrorhizon) have previously 
been shown to inhibit the growth of HIV in the H9 cell line (Chang and Yeung, 1988). 
It is interesting to note that the aqueous extract of P. vulgaris exhibited 
considerable inhibition (17-94% inhibition at 20-200 |ig/ml) on HIV-1 PR activity. 
Inhibition by the same extract was observed for virus/CD4 cell interaction and HIV-1 RT 
activity (Chang and Yeung, 1988; Collins et aL, 1997). P. vulgaris is a well-known 
Chinese medicinal herb for the treatment of fever. Previous research found that the herb 
contains a polysaccharide prunellin that may be attributed to its anti-viral effect (Tabba et 
aL, 1989). Our preliminary characterization however suggested that the active 
constituents might be mixtures of polyphenolic compounds. In contrast to the aqueous 
extract, the methanol extract of P. vulgaris did not show significant inhibition of HIV-1 
PR activity. 
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The methanol extracts of W. unigemmata, P. suffmticosa and S. suberectus 
caused more than 90% inhibition of HIV-1 PR activity at 200 ^g/ml. The inhibition by 
the methanol extracts from W. unigemmeta is of particular interest as Xu et al. reported 
similar inhibition by the aqueous extracts of a related plant W. orientalis (Xu et al, 
1996). A new class of glucoside (woodorien) isolated from an aqueous extract of the 
related plant was able to inhibit HSV-1, poliovirus type 1 and measles virus (Xu et al., 
1993). Further characterization is necessary in order to confirm whether woodorien is the 
active constituent for HIV-1 PR inhibition. 
In 1997，Collins and his colleagues have studied some of the aqueous extracts on 
HIV-1 reverse transcriptase (RT). As compared with our results on HIV-1 PR with their 
results on RT, the inhibitory effect of the aqueous extract of A. paniculata (~ 57%), C. 
morifolium (-85%), L. erythrorhizon (root ~ 43% and seed ~ 60%), S. scadens (~ 83%), 
V. yedoensis (~ 60%), W. unigemmata (~ 59%) and P. sujfruticosa (~ 59%) showed 
higher inhibitory activities than that of the aqueous extract inhibited on HI-1 RT (only 
0% or little inhibitory activity). It is suggested that the aqueous extracts of the both herbs 
are more effective on inhibiting HIV-1 PR rather than HIV-1 RT. 
In conclusion, a reliable assays for HIV-1 PR was established that greatly 
facilitates the efforts in the search for potent active constituents from Chinese medicinal 
plants for the inhibition of HIV-1 PR. 
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CHAPTER 3 
ISOLATION AND CHARACTEREATION OF ACTIVE CONSTITUENTS FROM 
THE METHANOL EXTRACTS OF WOODWARDIA UNIGEMMATA AGA^ST HIV-1 
PROTEASE 
3.1 Introduction 
We have previously examined 31 plant extracts for their inhibitory effects on 
HIV-PR. The results showed that six methanol extracts and five aqueous extracts had 
inhibitory effects on the HIV-1 PR enzyme. Among them, the methanol extract of 
Woodwardia unigemmata showed over 90% of inhibition on HIV-1 PR. The inhibition 
by the methanol extracts from W. unigemmata is of particular interest as Xu et al. 
reported similar inhibition by the aqueous extracts of the related plant W. orientalis (Xu 
et al., 1993). Further characterization is essential in the way to find out the active 
constituent from W. unigemmata for HIV-1 PR inhibition. 
Woodwardia unigemmata and its relatives are mainly found in the North, 
Northern West of the Mainland China. Their main functions are detoxification, heat-
cleaning, stop bleeding and kill worm. They are especially effective for the treatment of 
flu, fever, and blood in urine and feces (Huang, 1999). 
In this study, the methanol extract of Woodwardia unigemmatSL was further 
fractionated in the hope to identify the active constituents from the crude extract. 
56 
3.2 Materials and Methods 
3.2.1 Materials 
Tannic acid, Folin-Ciocalteau reagent, a-glucosidase, p-glucosidase, glycine, 
glucose, reserpine, (+) catechin, testosterone, vanillin, antimony trichloride reagent, p-
anisidine reagent, and Dragendorffs reagent were purchased from Sigma. 
Sephadex LH-20, ClO/20 column, and Gradifrac chromatographic system 
including recorder REC 102 and Readifrac were obtained from Amersham Pharmacia 
Biotech. 
Methanol (HiPerSolv), trifluoroacetic acid, acetonitrile (HiPerSolv), hydrochloric 
acid (HC1), and chloroform were obtained from BDH. 
Polyamide resin MN polyamide CC6 was purchased from Macherey-Nagel. 
The 0.22p,m filter was obtained from Micron Separation Inc. 
Vydac C18 protein/peptide reverse phase column 218TP was obtained from 
Separation Group. 
TLC plastic sheet (silica gel 60 F254; 20 x 20 cm) was obtained from MERCK. 
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3.2.2 Methods 
3.2.2.1 Methanol Extraction 
Dried rhizomes of Woodwardia unigemmata were cut into small pieces and 
chopped into fine powder with a food processor. The powder (lOOg) was soaked in 500 
ml of methanol for 7 days at 4�C. The herbal methanol extract was then filtered through 
Whatman Paper No. 1 to remove the insoluble material. The extract was then dried by 
Speedvac (Savant UVS400A) and kept at 4°C until use. 
3.2.2.2 Purification Procedures 
Sephadex LH-20 Chromatography 
The crude methanol extract was fractionated by size-exclusion chromatography 
on Sephadex LH-20 (Pharmacia) (Lu and Foo, 1997). Sephadex LH-20 was swollen in 
20% ethanol overnight and then packed in ClO/20 column connected to Gradifac 
chromatographic system. Crude methanol extract (20mg) was chromatograph on 
Sephadex LH-20 column with methanol increasing from 0% to 100% at a flow rate of 2 
ml/min. The eluate was monitored at UV280nm and 1ml per fraction was collected. 
Twenty fractions were collected and then dried by Speedvac (Savant UVS400A). HIV-1 
PR inhibitory activity was checked by fluorometric assays as described in 2.2.4.1. The 
fractions having the highest activity was further fractionated by reverse-phase HPLC. 
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Reverse Phase HPLC Purification 
The HPLC purification was done according to Lu et al. (1997). Reverse phase 
HPLC purification was performed on a Vydax Cig reverse phase column (Protein/peptide 
Reverse Phase Column 218TP) on Waters HPLC system. The starting buffer was 0.1% 
trifluoroacetic acid in nanopure water and eluting buffer was 100% acetonitrile with 0.1% 
trifluoroacetic acid. The column was eluted at a flow rate of 0.5 ml/min. The active 
fraction from Sephadex LH-20 chromatography was dissolved into 1ml of absolute 
methanol. After centrifugation at 13,000 rpm for 10 minutes to remove insoluble debris, 
the supernatant was then filtered through a 0.22^m filter. Fifty microliter fractions were 
applied to the reverse phase column. The extract was eluted at a flow rate of 0.6ml/min 
and the chromatogram was monitored at 320nm (486 Tunable Absorbance Detection). 
Two millilitre per fraction were collected on a Readifrac fraction collector. The eluate 
fractions were dried by SpeedVac system (Savant UVS400A). The dried extract was 
resuspended in absolute methanol until assay. The extract was eluted with a concentration 
gradient of starting buffer and eluting buffer as shown in the following table. 
Time Starting Buffer (0.1% Eluting Buffer (0.1% 
(minutes) trifluoroacetic acid in nanopure trifluoroacetic acid in 100% 
water) acetonitrile) 
一 0 “ 100 0 
一 40 “ 50 50 
— 4 5 50 50 
— 5 0 100 0 
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3.2.2.3 Removal ofTannins 
The tannins were removed from the crude extracts by polyamide adsorption 
method according to Wall et al. (1996). Polyamide resin (MN polyamide CC6) with 
particle size 0.1-0.3 mm was pre-swollen in double distilled water ovemight. (lg for 
every 5mg of samples applied). The resin was packed into a Poly-Prep chromatography 
column. The material (10 mg in 1 ml of double distilled water) was applied onto the 
column. The column was then eluted stepwise in four solvents: 10 ml of double distilled 
water, 10 ml double distilled water:methanol (1:1 v/v), 20 ml of absolute methanol, and 
20 ml of O.lM NaOH. The methanol-containing fraction was evaporated to dryness by 
using Speedvac (Savant UVS400A). The double distilled water eluate was frozen and 
lyophilized. The pH of NaOH eluate was adjusted to 6.5 with concentrated HC1. After 
neutralization, the eluate was dialyzed against 2 litre of double distilled water ovemight. 
The eluate was then frozen and lyophilized. All the methanol, water and 0.1 M NaOH 
eluates were subjected to fluorometric assay and Folin-Ciocalteau test for polyphenolic 
compound detection (Collins etal., 1998). 
3.2.2.4 Glucosidase Digestion 
The methanol extract of W. unigemmata was pre-treated with a- and p-
glucosidase in order to determine whether the inhibitory constituents may contain 
polysaccharides. The treatment with a-glucosidase or p-glucosidase was performed 
according to Collins et al (1997). For a-glucosidase, the HPLC purified eluate was 
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dissolved in 40^il assay buffer (50 mM 2-[N-morpholino]ethanesulfonic acid (MES)-
NaOH, pH 6.5) and then incubated with 10|il a-glucosidase (200U/ml) at room 
temperature for 15 minutes, the reaction was stopped by the addition of 2 M glycine-
NaOH, pH 10. For P-glucosidase digestion, sample was dissolved in 30p,l p-glucosidase 
buffer (50 mM NaOAc, pH 5.5) and then mix with 20|il p-glucosidase (lOOU/ml). The 
reaction was also incubated at room temperature for 15 minutes and was stopped by 
glycine-NaOH. 
3.2.2.5Analytical Thin Layer Chromatographic (TLC) 
The presence of known classes of phyto-chemicals was analyzed by TLC. Five 
percent of the samples from various purification steps were applied onto the TLC plate 
(MERCK silica gel F254). Samples were eluted with chloroform:acetone (8:2). For steroid 
detection, the TLC plates were stained by spraying with vanillin reagent, which showed 
yellowish color. For flavonoid detection, the TLC plates were sprayed with antimony 
trichloride, which showed yellowish color. For carbohydrate detection, the TLC plates 
were sprayed with p-anisidine solution, which showed the brownish color. For alkaloid 
compounds, the TLC plates were sprayed with Dragendorffs reagent, which showed the 
red-brownish color (Jork et al, 1990). 
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3.2.2.6 Acid Hydrolysis 
The procedure for acid hydrolysis was performed according to Tabba et aL (1989) 
and Lu et aL (1997). An amount (5mg) of HPLC-purified fraction was incubated in 2N 
HC1 at 100°C for 2 hours. After the hydrolysis, the acid hydrolyzed compound was 
partition into chloroform: water (1:1) using a separating funnel to separate the aqueous 
phase and the organic phases. The aqueous phase was dried by lypohilization while the 
organic phase was dried by Speedvac (Savant UVS400A). 
3.2.2.7 Electrospray Mass Spectrometry 
The electrospray mass spectra measurements were carried out on a Micromass 
Fisons VG Platform II’ controlling by the MassLynxTM data system connected to a 
personal computer using the Microsoft Windows for data acquisitiion and processing. 
Nitrogen was used as a sheath gas. Ions emerging from the mass analyzer were detected 
by the Dynolite™ detector system, and with a low noise photomultiper typically with a 
gain of 10^ amplifies the ion current collected. An amount of lmg of sample (dissolved in 
1ml of 50% acetonitrile) is introduced through the valve injection loop switching the 
sample plug into the mobile phase (50:50 mixture of acetonitrile and water), at a flow rate 
of 10^1/min. All the mass spectra were averaged with background subtracted. 
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3.2.2.8 Dose-response Curve 
The dose-response curves were constructed by a 10-fold dilution of samples 
starting from lOmg/ml. The samples included methanol crude extract, eluate from 
Sephadex LH-20 chromatography, eluate from the HPLC separation on Vydac Cig 
column, and the sample after 2N HC1 acid hydrolysis. The fluorometric assay was 
performed as mentioned in 2.2.4.1. 
3.2.2.9 Kinetic Studies 
The Lineweaver-Burk plots for proteolytic activity were determined in the 
presence and absence of methanol crude extract of W. unigemmata. The 
concentration of fluorogenic substrate was 2.5|xM, 5^M, lO^iM, 20)iiM, and 
40^M. The concentration of the methanol extract of W. unigemmata used was 
200p^g/ml. The fluorometric assay was performed as in 2.2.4.1. 
3.2.2.10 Activity ofthe HPLC-purifiedprinciple(s) on Other Aspartyl Proteases 
In order to test whether the HPLC-purified constituent(s) can also show inhibition 




Renin (human kidney) was purchased from Calbiochem. A fIurorometric method, 
which makes use of a synthetic peptide substrate for renin, was used to measure the renin 
enzyme activity in a fluorescence-based microplate reader. The reaction procedure is 
similar to the fluorometric method on HIV-1 PR, except that the fluorogenic substrate 
was (Arg-Glu(EDANS)-Ile-His-Pro-Phe-His-Thr-Lys(DABCYL)-Arg) (Holzman et al., 
1991; Wang et al., 1993). The substrate was dissolved in DMSO to make a lmM stock. 
The stock fluorogenic substrate was diluted to 100pM in the assay buffer (lOOmM 
sodium chloride, 50mM tris(hydroxymethyl)aminomethane, pH to 8.0). An aliquot ( _ ) 
of substrate and 3.5^il renin solution (1.3M,g/^ il) were added to the reaction mixture in the 
assay buffer in the presence (200^g/ml) and absence of tested extracts to make a final 
reaction volume of lOO i^l. The mixture was incubated at 37�C for 1 hour. After 
incubation, lO i^l of 5.5% trifluoroacetic acid (TFA) was added to stop the reaction. The 
fluorescence intensity was measured in a spectrofluorometer (Perkin Elmen LS50B) with 
an excitation wavelength of 340nm and an emission wavelength of 490nm (Wang et aL, 
1993). 
Pepsin assay 
Pepsin (porcine stomach mucosa) was purchased from Calbiochem. To confirm 
the proteolytic activity, the hydrolysis of a synthetic peptide substrate (Leu-Ser-p-nitro-
Phe-Nle-Ala-Leu-Ome, where Ome = methoxy and Nle = norleucine) by pepsin was 
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studied in the reaction assay (Cho and Northrop, 1998). An aliquot of 10)iM substrate 
and 5^iM pepsin solution were added to the reaction mixture in the assay buffer (50mM 
Tris-HCl’ pH 2.0，5mM CaCl2, 0.02% NaN3) in the presence (200^ig/ml) and absence of 
tested extracts to make a final reaction volume of lOOpi. The mixture was incubated at 
370c for 20 minutes. After incubation, lO i^l of 5% trichloroacetic acid (TCA) was added 
to stop the reaction. The hydrolysis of synthetic peptide was monitored by 
spectrophotometer at 300nm in a i^ Quant Biomolecular Spectrophotometer (BIO-TEK) 
(Fusek et aL, 1990; Lin et aL, 1994; Lin et al, 1992). 
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3.3 Results 
3.3.1 Purification of Methanol Extracts of Woodwardia unigemmata 
Since the methanol extract of W. unigemmata showed potent HIV-1 PR inhibitory 
activity in the preliminary screening, the inhibition activity of extract was further 
analyzed by using RP-HPLC assay at concentration 200^ig/ml and 20^i^g/ml. Product peak 
still found even at the concentration of 20^ig/ml (-37%) (Fig. 3.1). 
The crude methanol extract of W. unigemmata was purified by fractionation using 
Sephadex LH-20 chromatography. Figure 3.2 shows a typical chromatogram of the 
fractionation, two broad peaks were resolved (25% and 60% MeOH respectively). Each 
fraction was taken for HIV-1 PR protease assay. Fraction 4-9 shown the highest 
inhibitory activities (-85%) were pooled together for further analysis. 
The pooled fractions were further fractionated by reverse phase HPLC on a 
Vydax Cig reverse phase HPLC column. The chromatogram was monitored at OD215nm. 
The fractions were collected and examined for anti-HFV-l PR activity. Figure 3.3 shows 
that peak 2 exhibited the highest inhibitory activity (�80%). This fraction was loaded on 
the column for further purification. Figure 3.4 showed a nearly homogeneous peak after 
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Figure 3.1: Inhibition of HIV-1 protease by the methanol extract of Woodwardia 
unigemmata by RP-HPLC. (a) Inhibition HIV-1 PR activity by 200^ig/ml of W. 
unigemmata methanol extract, (b) Complete inhibition of HIV-1 PR activity by 
pepstatin A preincubation, (c) Inhibition HIV-1 PR activity by 20^ig/ml of W. 
unigemmata methanol extract. S refers to peptide substrates peak. P refers to the 
product peptide after HIV-1 PR cleavage on substrates. 
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Figure 3.2: The profile of inhibitory activities on HIV-PR of crude methanol extract of 
Woodwarida unigemmata on Sephadex LH-20 chromatography. The eluates were dried 
by speedvac and the residue was resuspended in 1 ml of absolute methanol. An amount of 
200 ^ig/ml from each fraction was used to perform HIV-PR fluorometric assay. Active 
fractions 4 — 9 were pooled together and further fractionated by HPLC separation on a 
Vydac Ci8 reverse-phase column. 
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Figure 3.3: The profile of HIV-1 PR inhibitory activity from RP-HPLC fractionation 
methanol extract of W. unigemmata. Pooled active fraction from Sephadex LH-20 of the 
fraction 4-9 was further fractionated on a Vydax Ci8 column. An amount of 5 mg/ml of 
the extract resulted from Sephadex LH-20 eluates were loaded onto the Vydax Cig 
column. The extract was eluted with a linear gradient from 0 - 100% acetonitrile at 
0.5ml/min and chromatogram was monitored at wavelength 215nm. Four main peaks 
were found and they were collected, dried by Speedvac. An amount of 200 ^g/ml of the 
eluate of fraction was used for HIV-1 PR fluorometric assay. 
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Figure 3.4: RP-HPLC fractionation of the methanol extract of W. unigemmata. The peak 
2 of previous RP-HPLC purification was reloaded onto a Vydax Cig column, eluted with 
a linear gradient of acetonitrile in 0.1% TFA (0-100% acetonitrile in 50 minutes at 
0.5ml/min). An amount of 5mg/ml of sample was applied onto the column. Two-ml 
fractions were collected and dried by Speedvac. An amount of 200 [ig/ml of the eluate of 
fraction was used for HIV-1 PR fluorometric assay. Peak a showed the highest inhibitory 
activity (-70%). 
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3.3.2 Removal of Tannins 
The tannins were eliminated by adsorption chromatography on a column of 
polyamide resin (Collins et al., 1998). After sample loading, the column was eluted with 
different concentration of methanol and then with O.lM NaOH. The presence of 
polyphenolic compounds was tested by Folin-Ciocalteau test (Collins et al., 1998). Figure 
3.5 showed a standard curve for tannic acid assayed with Folin-Ciocalteau reagent was 
constructed with measurement of various concentration of tannic acid (0-100^g) under 
OD700. It was found that the O.lM NaOH eluate contained most of the polyphenolic 
compounds while there are only trace amount of phenolic compounds in the combined 
methanol eluate. 
Two group of eluates (all methanol fractions and O.lM NaOH fractions) were 
subjected for protease assay. It was found that the percentage of inhibition of combined 
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Figure 3.5: Standard curve of tannic acid assayed with Folin-Ciocalteau reagent. The 
absorbance was linear over the range 0-100|Lig of tannin standard. The detection limit of 
the assay was 2.5p.g. The assay was carried out by addition of 500^il sample into 1ml of 
Folin-Ciocalteau reagent. Then 3.5ml of 20% Na2CO3 and 5ml of water were added into 
the solution. The mixture was kept at room temperature for 10 minutes for color 
development. The color of mixture changed to dark blue in the presence of tannin-like 
compounds. The absorbance was measured at OD700nm. 
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Table 3.1: The effect of tannin-like compound on HIV-1 PR inhibition. 
Sample % Inhibition Folin-Ciocalteau test 
Crude extract 91.96 + 6.48 + 
Methanol eluate from polyamide resin 84.17 土 1.32 -
0.1 M NaOH eluate from polyamide resin 20.86 土 0.67 + 
An amount of lOmg/ml was applied into a polyamide column. The column was then 
eluted in four stepwise solvents: 10 ml of double distilled water, 10 ml double distilled 
water:methanol (1:1), 20 ml of absolute methanol, and 20 ml of O.lM NaOH. All the 
methanol, water and 0.1 M NaOH eluates were subjected to fiuorometric assay and Folin-
Ciocalteau test for polyphenolic compounds. The concentration of samples for 
fiuorometric assay were 200 jig/ml. Values are mean H^S.E.M. with n=3. (+): Positive 
result. Color change from yellow to dark blue. (-): Negative result. Color unchanged 
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3.3.3 Glucosidase Digestion 
It has been reported that a related plant species Woodwardia orientalis contained 
an active component of glucoside called woodorien, which exhibited antiviral activity 
against HSV-1, poliovirus type 1，and measles virus (Xu et al, 1993). The possibility that 
similar activity was found in Woodwardia unigemmata was examined by digesting with 
glucosidase on the HPLC purified extract. The HPLC purified active compound from W. 
unigemmata was therefore treated by a- and P_ glucosidase in the way to find out if the 
inhibitory effect is due to the presence of a- or P_ glucoside linkage or not. It was found 
that treatment of a-glucosidase digestion did not affect the inhibitory effects on HIV-1 
PR. In the case of P-glucosidase digestion, there still have about 60% inhibition activity 
on HIV-1 PR. It is suggested that the treatment with a- and P_ glucosidase did not modify 
the inhibitory activities on HIV-1 PR (Table 3.2). 
3.3.4 Acid Hydrolysis 
To further characterize whether the inhibitory activities from methanol extract of 
W. unigemmata contain any sugar moiety. The HPLC purified active fraction was 
digested by acid hydrolysis to remove sugars (Tabba et aL, 1989 and Lu et al, 1997). 
After acid hydrolysis, the digested sample was partitioned in chloroform/water 
fractionation to separate the hydrolyzed and non-hydrolyzed compounds. TLC was 
carried out to identify the hydrolyzed compounds after the acid hydrolysis (Fig. 3.7). 
Fluorometric protease assay was carried out. It was found that there was no significant 
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inhibitory effect on the water fraction on anti-HIV-1 PR activity. While the chloroform 
fraction still exhibited inhibitory effects (-65% inhibitory activities) (Table 4). Figure 3.6 
shows the HPLC profiles of non-hydrolyzed and hydrolyzed compounds. 
3.3.5 Analytical Thin Layer Chromatography 
Analytical TLC was performed on the eluates collected during each of 
purification procedure to determine the identity of the active constituents. The color 
development reagent was purchased from Altech. The results we're shown in Figure 3.7. 
For carbohydrate detection (Fig. 3.7a)’ a brown spot would appear if the samples 
contain sugar after spraying with p-anisidine. As shown in the figure, a brown spot was 
shown in the glucose standard having a Rf value of 0.7. The crude extract showed two 
yellow smear spots with Rf value of 0.38 and 0.68. The sample from Sephadex LH-20 
chromatographic purification showed two yellow spots with Rf value of 0.36 and 0.68. 
The lane contains the sample of aqueous phase after acid hydrolysis showed only one 
yellow spot with Rf value of 0.68. No spot present in the lane contains sample from 
organic phase after acid hydrolysis. 
For alkaloid detection (Fig. 3.7b)，a reddish brown color would appear if the 
samples contain alkaloid-like compounds after spraying with Dragendorff's reagent. A 
red-brown spot was produced in the reserpine standard having a Rf value of 0.63. Two 
smear spots were present with Rf value of 0.38 and 0.68 in the lane of crude extract. The 
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Sephadex LH-20 gel purified sample also showed two red-brown spots with Rf value of 
0.36 and 0.68. No color spot showed in the lane contains sample of aqueous phase after 
acid hydrolysis. There was a reddish brown spot having a Rf value of 0.68 showed in the 
lane contains sample of organic phase after acid hydrolysis. 
For flavonoid detection (Fig. 3.7c)’ a yellow color would appear if the samples 
contain flavonoid or flavone after spraying with antimony trichloride reagent. A yellow 
spot was produced in the (+)-catechin standard having a Rf value of 0.62. The crude 
extract showed two yellow smear spots with Rf value of 0.36 and 0.72. A small yellow 
spot was present in the lane contains sample from Sephadex LH-20 chromatographic 
purification with Rf value of 0.7. No color spot was shown in the other lanes. 
For steroid detection (Fig. 3.7d), a yellow color would appear if the samples 
contain steroid compounds after spraying with vanillin. A yellow spot was shown in the 
testosterone standard having a Rf value of 0.5. The crude extract showed two yellow 
smear spots having Rf value of 0.29 and 0.59. A small yellow spot was present in the lane 
of Sephadex LH-20 chromatographic purified sample with Rf value of 0.28. No color 
spot was shown in the other lanes. 
It was concluded that the active constituents might be carbohydrates containing 
alkaloid-like compounds and carbohydrate-like compounds (Fig. 3.7). 
76 
Table 3.2: Effect on glucosidase digestion of methanol extract of W. unigemmata on 
HIV-1 PR activity. 
Sample % inhibition 
No digestion 70.37 + 0.86 
a-glucosidase 60.85 土 0.91 
p-glucosidase 60.94 土 0.57 
For a-glucosidase, lmg/ml of HPLC-purified samples was incubated with a-glucosidase 
at room temperature for 15 minutes; the reaction was stopped by the addition of 2 M 
glycine-NaOH, pH 10. For P-glucosidase digestion, 1 mg/ml of sample was incubated 
with p-glucosidase at room temperature for 15 minutes and was stopped by glycine-
NaOH. The concentration of samples, used in fluorometric measurement, were 200 
M-g/ml. Values are mean 土 S.E.M. with n=3. 
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Table 3.3: Effect of acid hydrolyzed W. unigemmata methanol extract on HIV-1 PR 
inhibition. 
Sample % of inhibition 
Chloroform fraction 64.84 土 1.78 
Distilled water fraction 7.76 土 2.34 
An amount of 5mg of HPLC-purified fraction was incubated in 2N HC1 at 100°C for 2 
hours. After the hydrolysis, the acid hydrolyzed compound was partition into chloroform: 
water (1:1) using separating funnel to separate the aqueous phase and the organic phases. 
An amount of 200^g/ml of hydrolyzed and non-hydrolyzed sample were used for 
fluorometric assay. Values are mean 土 S.E.M. n=3. 
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Figure 3.6: HPLC fractionation the methanol extract of W. unigemmata 
before (a) and after (b) acid hydrolysis. The samples were fractionated 
onto a Vydax Ci8 column by RP-HPLC, eluted with a linear gradient of 
acetonitrile in 0.1% TFA (0-100% acetonitrile in 30 minutes at 
0.6ml/min). A near homogeneous peak appear and an amount of 200 
M-g/ml of the eluate of fraction was used for HIV-1 PR fluorometric assay. 
The near homogeneous peak was shift to the right after acid hydrolysis 
indicating an increase in hydrophobicity of the hydrolyzed active 
constituent. 
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Figure 3.7: Thin layer chromatography on the methanol extract of W. 
unigemmata. Five percent of sample was added onto each lane. Samples were 
eluted with chloroform:acetone (8:2). Plate A is for the carbohydrate detection. 
Plate B is for the alkaloid detection. Plate C is for the flavonoid detection. Plate D 
is for the steroid detection. Lane 1 is the standard (For plate A: glucose; plate B: 
reserpine; plate C: (+) catechin; plate D: testosterone). Lane 2 is the crude 
methanol extract of W. unigemmata. Lane 3 is the active fractions from Sephadex 
LH-20 chromatography. Lane 4 is the active fractions of RP-HPLC. Lane 5 is the 
aqueous phase after 2 N HC1 acid hydrolysis. Lane 6 is the chloroform phase after 
2 N HC1 acid hydrolysis. 
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3.3.6 Electrospray Mass Spectrometry 
In order to obtain more information on the molecular mass of the unknown 
sample, electrospray mass spectrometer analysis of the sample was carried out. 
Under the condition described in the materials and methods section, the MW of 
the RP-HPLC purified compound is about 6000 (Fig. 3.8a), while the MW of the 
RP-HPLC purified after acid hydrolysis is about 338 (Fig. 3.8b). 
3.3.7 Dose-response Inhibition of HIV-1 Protease 
Dose-response curves of the methanol extract of W. unigemmata were 
carried out. Samples from crude extract, Sephadex LH-20 chromatography, HPLC 
purification on Vydac Cig column, and after acid hydrolysis were performed. 
Figure 3.9a shows the dose-response curves of samples of extract from fractions 
of RP-HPLC purified peak as described in the previous section. For sample after 
HPLC purification, the IC50 ~ 15^iM. Figure 3.9b shows the comparison of dose-
response curve between sample before and after 2N HC1 acid hydrolysis. It was 
found that the I C 5 0 of sample after acid hydrolysis (removal of sugar moiety) is 
about 7^iM, while the I C 5 0 of sample before acid hydrolysis is about 15^M. 
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Figure 3.9a: Dose-response curve of W. unigemmata on inhibition to HIV-
1 protease. Percentage inhibition is calculated as the percentage of 
inhibition of fluorescence intensity in the presence and absence of 
samples. Line with black circle represents the methanol crude extract. Line 
with clear circle represent the sample after passing through Sephadex LH-
20 chromatography. Line with black triangle represents the sample after 
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Figure 3.9b: Dose-response curve of W. unigemmata on inhibition to HIV-
1 protease. Percentage inhibition is calculated as the percentage of 
inhibition of fluorescence intensity in the presence and absence of sample. 
The concentration was calculated according the molecular weight from the 
mass spectrometric analysis. Line with black triangle represents HPLC-
purified sample before acid hydrolysis. Line with black circle represents 




3.3.8 Kinetic Studies 
The results of kinetic studies on crude methanol extract of W. unigemmata 
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Figure 3.10: Inhibition mode of methanol extract of W. unigemmata. The 
concentration of substrate used was 2.5pM, 5^iM, lO^iM, 20(j,M, and 
40p.M. The concentration of methanol extract of W. unigemmata used was 
200^ig/ml. Line with black square represent the inhibition to HIV-1 
protease with methanol extract of W. unigemmata and line with black 
circle represent the inhibition to HFV-1 protease without methanol of W. 
unigemmata. 
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3.3.9 Effects of HPLC-purified Active Principle on Other Aspartyl Proteases 
In order to investigate whether the active principle from W. unigemmata is 
selective towards HIV-1 PR, the same extract was examined for its ability to 
inhibit other aspartyl proteases such as renin and pepin. 
Renin activity was measured using a fluorogenic peptide substrate for 
renin (Holzman et aL, 1991; Wang et aL, 1993). The substrate, (Arg-
Glu(EDANS)-Ile-His-Pro-Phe-His-Thr-Lys(DABCYL)-Arg) has an excitation 
maximum at 340nm and an emission maximum at 490nm when hydrolyzed by 
renin. Pepsin activity was determined by measuring the rate of hydrolysis of the 
synthetic peptide Leu-Ser-p-nitro-Phe-Nle-Ala-Leu-Ome (Cho and Northrop, 
1998; Lin et aL, 1992). As shown in Table 3.4, the HPLC-purified extracts 
inhibited renin by -14% at the concentration of sample of 200p.g/ml, whereas 
inhibition on pepsin was only �4 .6% at the concentration of sample of 20^g/ml. 
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Table 3.4 Effects of HPLC-purified extracts from W. unigemmata on other 
aspartyl protease. 
% inhibition 
HIV-1 PR 91.96±6.84 
Renin 13.40±0.6 
Pepsin 4.61±1.38 
For renin assay, lOp,M of fluorogenic substrate, 5|xM renin solution and 200^ig/ml of 
sample were added to the reaction mixture in an assay buffer. The mixture was incubated 
at 3TC for 1 hour and stopped with addition of trifluoroacetic acid (TFA). The 
fluorescence intensity was measured in a spectrofluorometer (Perkin Elmen LS50B) with 
an excitation wavelength of 340nm and an emission wavelength of 490nm. For pepsin 
assay, an amount of 10|iM synthetic substrate，5jjM pepsin solution and 200^ig/ml of 
sample were added to the reaction mixture, and then incubation at 37°C for 20 minutes. 
The activity was measured by i^ Quant Biomolecular Spectrophotometer at 300nm. 
Values are mean +_S.E.M. with n=3. 
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3.4 Discussion 
As shown in Chapter 2, the methanol extract of W. unigemmata exhibited 
inhibition higher than 90% and the activity could not be removed by a de-tannized 
procedure. This preliminary study suggest that a non-tannin-like natural product is 
present in the methanol extract of W. unigemmata possessing potent inhibitory activity on 
HIV-1 PR. 
The aqueous extract of W. unigemmata was shown to be capable of inhibiting the 
interaction between immobilized CD4 receptor in vitro, with a high degree of potency 
(>80%). But the same extracts had no inhibitory activity at all against HIV reverse 
transcriptase (Collins et aL, 1997). We have extended these findings that the methanol 
extracts of W. unigmmata were inactive against HIV reverse transcriptase. In contrast, the 
methanol extracts, but not the aqueous extract, of W. unigemmata showed over 90% 
inhibition on HIV-PR at 200^ig/ml. 
Tannins are water-soluble polyphenols that comprise a group of secondary 
metabolites. They have been found in a variety of plants utilized traditionally in the 
preparation of leather. Apart from this, tannins are known their abilities to affect a wide 
number of biochemical reactions due to their high affinity for proteins. For example, 
tannins have been shown to inhibit HIV-1 reverse transcriptase and the binding of HIV-1 
gpl20 to the CD4 T-cell receptor (Collins et aL, 1997; Houghton, 1996; Tan et aL, 1991). 
Thus, they are generally considered to be non-specific inhibitors of HIV-1 viral enzymes 
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(Kusumoto et aL, 1995). In order to increase the chance of identifying novel inhibitors of 
HIV-1 PR, the tannins presents in many plant extracts are removed firstly by adsorption 
chromatography on polyamide column. The method is simple, reproducible and more 
effective than other methods (such as PVP precipitation) (Wall et al., 1969). It is because 
the non-tannins and tannins substances can be separated in a short time (Tan et al., 1991). 
Collins et al. (1998) showed that this method is ideal for the complete removal of 
polyphenolic compounds (such as tannins) from up to 5 mg plant extracts. The non-
tannin constituents were washed off from the column while tannins were retained on the 
column. The tannin-like constituents were washed off by elution with 0.1 M NaOH. Both 
fractions from the column were subjected to HIV-1 PR fluorometric assay. The contents 
of polyphenolic compounds were determined by Folin-Ciocalteau reagent (Collins et al., 
1998). The methanol eluates were found negative for the presence of tannins (Table 3.1). 
The tannin-enriched fraction (i.e. the O.lM NaOH eluate), showed only about 20% of 
inhibition on HIV-1 PR while the tannin-free fraction (i.e. methanol eluate), still showed 
about 80% of inhibition on HIV-1 PR. This result suggested that the active constituent(s) 
is/are not tannin-like chemicals. 
The dried rhizome of W. unigemmata has been used for many centuries in China 
as anthelmintis. The rhizome contains inokosterone, woodwardic acid, and woodorien 
(Huang, 1999). In 1993, Xu et al. published a report showing that the aqueous and 
methanol extracts of the rhizomes of Woodwardia orientalis exhibited antiviral activity 
against HSV-1, poliovirus type 1，and measles virus. The active compounds responsible 
for the activity in W. orientalis are mainly due to a glucoside (woodorien) (Xu et aL, 
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1993). To confirm whether the same activity is responsible for HIV-1 PR inhibition, the 
HPLC purified active compound was subjected to a- and P_ glucosidase digestion in 
order to remove the glucoside. It was found that neither a-glucosidase nor ^-glucosidase 
digestion failed to abolish the inhibitory activities suggesting that the active constituents 
may not be due to the woodorien present in W. unigemmata (Table 3.2). 
In order to isolate the active constituent(s), the methanol extract of the rhizome of 
W. unigemmata was successively fractionated using Sephadex LH-20 size-exclusion 
chromatography and aliquots of each fraction were used to determine inhibitory activities 
by fluorometric assay as previously described (Fig. 3.2). The active fractions were then 
pooled together (from fraction 4-9), concentrated and then subjected to reverse-phase 
HPLC separation on a Vydax Cis protein/peptide reverse phase column 218TP. A major 
peak (Fig. 3.3b peak a), elute at -15% acetonitrile, elicited strong inhibition to HYV-\ PR. 
The unknown was identified as glycoalkaloid-like compound on the basis of the 
analytical TLC analysis (Fig. 3.6). 
The carbohydrates are then broken up from alkaloids by acid hydrolysis by a 
method modified from Lu et al. (1997). Two fractions were obtained after the partition of 
hydrolyzed products into two solvent systems, chloroform and water (1:1). Our results 
showed that the sugar partitioned into the water phase while the chloroform fraction 
contained alkaloids as detected by TLC analysis (Fig. 3.6a & b). Both the water-soluble 
and chloroform-soluble fractions were dried and aliquots of which were used for HIV-1 
PR assay activity. There were a little inhibitory activity (~7%) found in the water phase 
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(carbohydrates) subjected for the protease fluorometric assay. Almost 65% inhibitory 
activities retained in the organic phase, which was found to contain an alkaloid-like 
chemical (Rf = 0.68)(Table 3.3). Further analysis with HPLC separation on Vydex Cig 
column to determine if there is any significant change in the retention time of the active 
constituents. It was found that the retention time of the active compound shift to the right, 
indicating that the compound became more hydrophobic (from 14 minutes change to 35 
minutes) (Fig. 3.6). 
The molecular masses of HPLC-purified active compound with or without acid 
hydrolysis were further confirmed by electrospray mass spectrometry (Fisons VG 
Platfrom II). It was suggested that the mass of the non-acid-hydrolyzed active principle 
was a MW of about 6000 (Fig. 3.8a), while that of the acid-hydrolyzed active compound 
was the MW of ~ 338 (Fig. 3.8b). However, the I C 5 0 of the acid-hydrolyzed compound is 
higher than that of the non-hydrolyzed compound. It may suggest that the carbohydrates 
from the active compound account for part of the inhibitory activity on HIV-1 PR. 
The specificity of the HPLC-purified extract was examined by comparing the 
inhibition on the activity of renin and pepsin. It is found that the purified extract 
specifically inhibited the HIV-1 PR activity, with little inhibition on other aspartyl 
proteases, renin and pepsin (Table 3.4). For protease renin, the fluorogenic peptide 
substrate has been linked to a fluorophore (5-(aminoethyl)aminoaphthalene sulfonate, 
EDANS) at one end and to a non-fluorescent chromophore (4'-
dimethylaminoazobenzene-4-carboxylate, DABCYL) at the other. The acceptor 
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DABCYL chromophore was chosen for maximal overlap of its absorbance with the 
emission spectrum of the EDANS fluorophore, resulting in quenching of the nearby 
EDANS through resonance energy transfer. After cleavage by renin, the product 
(peptide-EDANS) is brightly fluorescent under excitation and emission wavelength of 
340nm and 490nm respectively (Holzman et al, 1991; Wang et al., 1993). The assay is 
similar to the fluorogenic substrate used in the determination of HIV-1 PR activities. The 
renin activity was monitored by an increase in fluorescence intensity upon cleavage of 
the fluorogenic substrate. For protease pepsin, we study the proteolysis of the synthetic 
peptide Leu-Ser-p-nitro-Phe-Nle-Ala-Leu-OMe by pepsin. The formation of proteolytic 
products, Leu-Ser-p-nitro-Phe and Nle-Ala-Leu-OMe resulted in a changed of 
absorbance at 300nm (Cho and Northrop, 1998; Fusek et al, 1990; Lin et al., 1992). 
Figure 3.10 illustrated the mode of inhibition action of the methanol extract of W. 
unigemmata. It showed that it is competitive inhibition. That means the unknown 
constituents may act as a competitive inhibitor activity on the active site of the HIV-1 PR. 
However, the exact mechanism of action awaits further determination. 
In conclusion, an alkaloid-like compounds was successfully isolated from the 
methanol extract of W. unigemmata having strong inhibition on HIV-1 PR activity 
successfully. However, the structure has still not been elucidated. Therefore, further 
characterization in future study to elucidate the chemical nature of the active 
substance(s). Moreover, the isolation and characterization of anti-HIV-1 PR substances 
from other crude extracts is now in progress. 
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CHATPER 4 ‘ 
mENTffICATION OF SELECTIVE RNA APTAMERS AGAD^ST HW-l 
PROTEASE BY SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL 
ENRICHMENT (SELEX) 
4.1 Introduction 
The SELEX (Systematic Evolution of Ligands by EXponential enrichment) is 
a novel strategy to isolate high affinity oligonucleotides from a random pool of 
variant nucleic acid sequences that bind a target molecule. It is based on the in vitro 
selection of high-affinity oligonucleotide ligands (RNA or DNA) through systematic 
enrichment by PCR amplification and sequences identification motif. 
Tuerk and Gold (Tuerk and Gold, 1990) was the first group of researchers to 
introduce the first RNA aptamer that interacts with bacteriophage T4 DNA 
polymerase. They described this new combinatorial technique as SELEX (Systematic 
Evolution of Ligands by EXponential enrichment). They constructed a 92-nucleotide 
transcript that contained a 36-nucleotide sequence as the entire RNA recognition site 
for T4 DNA polymerase flanked by primer annealing sequence information for the 5’ 
and 3' oligonucleotides used in PCR. They also incorporated completely random 
sequences in 8 nucleotides. Four rounds of selection by T4 DNA polymerase as target 
molecule on nitrocellulose filters followed by replicative and in vitro transcription 
steps generated a pool of high-affinity RNA sequences that was composed of two 
major sequence motifs. One sequence was the wide-type sequence, AAUAACUC, 
found in the bacteriophage mRNA. The other sequence was a variant, AGCAACCU, 
that differed from the wild type at four positions, formed a different secondary 
structure by extending the operator hairpin by two more base pairs, and bound to T4 
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DNA polymerase equivalently well. Thus, they established a technique that selected a 
sequence motif, which can associate with RNA recognition site and can inhibit the 
polymerase function of the enzyme. The selected sequence with high affinity and 
specificity to the target molecule was the called "aptamers" (Kraus et aL, 1998). 
Ellinigton et aL (1990) showed that the SELEX approach is also possible to select 
RNA aptamers that are able to specifically interact with complex organic molecules of 
low molecular weight, thus serving as receptor molecules based on nucleic acids 
rather than proteins (Ellington and Szostal, 1990). 
The SELEX technique has now been applied to different molecules from 
targets such as organic dyes, amino acids, biological cofactors, antibiotics, peptides 
and proteins or even whole viruses (Bell et aL, 1998; Ellington and Szostal, 1990; 
Kraus et aL, 1998; Pan et aL, 1995). Table 4.1 summarizes the recent research 
applying the techniques of SELEX. 
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Table 4.1: A summary of the recent works on therapeutic or diagnostic 
application using SELEX. 
Target Molecule Dissociation Possible therapeutic Reference 
constant (nM) and/or diagnostic 
of aptamers application 
IgE 10.0 Allergic disease (Wiegand et al., 
1996) 
Interferon y (ffN-y) 6.8 Inflammation and (Kubik et al., 1994) 
immune response 
L-selectin 3.0 Inflammation (0'Connell et al., 
1996) 
CD4 N/A Immune response (Kraus et aL, 1998) 
Basic fibroblast 0.350 Angiogenesis (Jellinek et al., 1993) 
growth factor 
(bFGF) 
Platelet derived 0.1 Tumor development . (Green et al., 1996) 
growth factor 
(PDGF) 
Rous sarcoma virus 40.0 Viral infection (Pan et al., 1995) 
(RSV) 
HIV-1 RT 1.0 Viral replication (Schneider et al., 
1995; Tuerk et al., 
1992) 
HIV-1 integrase 10.0 Viral replication (Allen et al., 1995) 
HIV-1 rev N/A Viral replication (Giver et al., 1993) 
a-thrombin 25.0 Thrombosis (Griffin et al., 1993) 
Protein tyrosine 18.0 Oncogenesis, viral and (Bell et al., 1998) 
phosphatases cellular regulation 
(PTPase) 
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The advantages of oligonucleotides as aptamers are of the fact that they 
contain defined sequence that serve as recognition sites for the binding of various 
regulatory and catalytic proteins. The RNA structural information is crucial to a 
variety of biochemical functions (Riordan and Martin, 1991; Tuerk and Gold, 1990). 
Study of the in vitro selection of aptamers has been proven a powerful tool as 
potential tools for dissecting the life cycle of the HIV-1. Several studies have used the 
SELEX procedure to obtain high-affinity RNA ligands against the reverse 
transcriptase (RT), the gag polyprotein, the Rev and Tat proteins and integrase of 
HIV-1. • 
Selective RNA and ssDNA aptamers which recognize HIV-1 RT have been 
reported (Tuerk et aL, 1992; Tuerk and Waugh, 1993; Schneider et aL, 1995). Tuerk 
et. al. (1992) identified a selected aptamers exhibit a RNA pseudoknot structure with 
an intramolecular base pairing between the conserved and non-conserved region. 
Moreover, the selected aptamers were selectively discriminated between various RTs, 
showing high affinity and specificity for HIV-1 RT whereas they did not bind to avian 
myeloblastosis virus (AMV) RT or Moloney murine leukemia virus (MMLV) RT 
(Tuerk et aL, 1992). Schneider et. al. (1995) found that the isolated ssDNA aptamers 
were able to inhibit the DNA polymerase activity of HIV-1 RT, with values of Ki as 
low as 0.3nM (Schneider et al., 1995). 
Giver et al. (1993) selected and designed high-affinity RNA ligands that can 
bind HIV-1 Rev protein better than the /?ev-binding element (RBE), which localized 
within the i^^v-responsive element (RRE). This RNA ligand has up to 16-fold tighter 
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than minimal RBE (Giver et al., 1993). They also showed that the RNA aptamers, 
derived against the HIV-1 Rev protein, can mediate Rev function in vivo (Nelson et 
al-, 1996). This is an impressive example that describes the in vivo functionality of an 
RNA aptamer. Tuerk et. al. (1993) also conducted SELEX to provide an RNA 
aptamer for the HIV-1 Rev protein. Three motifs (I’ II, IE) were found, and the 
affinity data confirmed that motif I defines the highest affinity ligands to Rev protein. 
They hypothesized that the motif II defines an RNA sequence motif that interacts with 
one binding site on Rev protein while the motif III define another site. That the two 
binding interactions are combined in motif I that constitute the high-affinity for the 
ligands (Tuerk et al.，1993a; Tuerk and Waugh, 1993b). • 
Tuerk and his colleagues (1993) reported the isolation of high-affinity RNA 
aptamers on HIV-1 viral protein, Tat protein, which is essential for the activation of 
transcription in the long terminal repeat (LTP) of the viral genome. The activation 
requires TAR RNA, the transcribed RNA contained a specific hairpin structure with a 
trinucleotide bulge (Karn, 1993). Tuerk and his colleagues isolated high-affinity 
RNA-Tat ligands that could inhibit Tat protein. 
Allen et. al. (1995) selected RNA aptamers directed against HIV-1 integrase 
(m). After eighteen rounds of SELEX were done and able to isolated individual RNA 
aptamer with the highest affinity toward HIV-IN. The structure of the aptamer, P5, 
was characterized using computer modeling and analyzed by chemical and enzymatic 
probing. It is suggested that there is an interaction between the looped-out fixed 
nucleotides and the nucleotides from the randomized region (Allen et al., 1995). 
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Lochrie et. aL (1997) demonstrated that the in Wfn>selected RNA aptamers 
against the gag polyprotein from SELEX can bind to two different proteins within gag 
polyprotein, matrix protein and nucleocapsid protein. They concluded that (1) a ligand 
that binds to smaller domains of a protein may also bind to the entire protein. (2) a 
protein may have more than one nucleic acid binding site, SELEX experiment can 
isolate ligands that bind to those site on the protein. (3) it is possible to isolate a ligand 
that binds to two or more RNA binding sites on a protein if that proteins has more 
than one RNA binding sites (Lochrie et aL, 1997). 
Using similar approach, selective RNA ligands that are able to bind HIV-1 PR 
were identified in this study. 
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4.2 Materials and Methods 
4.2.1 Materials 
Primer 1，GCG GAA TTC TAA TAC TAC TCA CTA TAG GAG ACA GTC 
CGA GCC; DNA template, GGA GAC AGT CCG AGC C(N)40 GGG TCA ATG 
CGT CAT A; and primer 2’ GCG GGA TCC TAT GAC GCA TTG were synthesized 
by GffiCO BRL (Life Technologies). 
MgCl2, dNTPs (dATP, dCTP, dTTP, and dGTP), 10 i PCR buffer, Taq DNA 
polymerase, Ultra-pure agarose, 10 x transcription buffer, UTP, T7 RNA polymerase, 
cloned RNase inhibitor, DNase I，RNase-free solution, Ultra-pure phenol, 
THEMOSCRffTM reverse transcription kit, EcoRI, BamHI, and 10 x PBS were 
purchased from GDBCO BRL (Life technologies). 
DIG RNA labeling kit, CDP-Star® substrates, and non-radioactive assay kit 
for reverse transcriptase were obtained from Roche-Boehringer Mannheim. 
Bovine serum albumin (BSA), chloroform/isoamylalcohol, Tris-base, KC1, 
NaCl, MgCl2, dithiothretiol (DTT), Tween-20, EDTA, and pepstain A were purchased 
from Sigma. 
Ethanol (analytical grade.) was obtained from BDH. 
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Protein G Plus/ Protein A Agarose bead, renin, and renin were purchased from 
Calbiochem. 
Fluorogenic substrates for HIV-1 PR, and fluorogenic substrates for renin 
were obtained from Molecular probes. 
F8 Maxisorp Loose NUNC-MMUNO Module was obtained from NUNC" 
GeneAmp® PCR System 9700 was obtained from Applied Biosystem. 
1^ Quant Biomolecular Spectrophotometer was obtained from BIO-TEK. 
4.2.2 Methods 
The SELEX experiment was conducted as described by Tuerk and Gold 
(1990) (Tuerk and Gold, 1990) with some modifications. Basically, there are three 
fundamental steps in any in vitro selection protocol. First a large pool of randomized 
sequences is generated, usually by chemical synthesis of DNA oligonucleotides that 
contain a region of random sequence flanked by constant regions that allow 
amplification and transcription. A typical library has a complexity of about 10'^ 
(Ellington and Szostal, 1990; Kraus et al., 1998). When RNA molecules are to be 
selected, this DNA pool is transcribed in vitro into RNA. Second, the pool of 
molecules is selected based on the ability of high affinity by a target ligand. Third, the 
small amount of oligonucleotides that separated from the unbound one is PCR-
amplified in vitro. The amplified oligonucleotides is then subjected to additional 
102 
rounds of selection and amplification until the pool is enriched in active sequences to 
the point that most of the pool material bind the target molecule at high affinity. At 
this point the pool can be cloned, sequenced, and characterized. 
4.2.2.1 PCR Amplification for the Generation ofa Double-Stranded DNA Library 
The DNA templates for used in SELEX have a variable region, created by 
mixed nucleotide incorporation during oligonucleotide synthesis by polymerase chain 
reaction (PCR). This was done by using three oligonuleotides: primer 1，GCG GAA 
TTC TAA TAC TAC TCA CTA TAG GAG ACA GTC CGA GCC (5' fixed region 
containing an Eco R1 site and the T7 promoter); template, GGA GAC AGT CCG 
AGC C(N)40 GGG TCA ATG CGT CAT A (template for PCR reaction containing 
40 randomized nucleotides); and primer 2’ GCG GGA TCC TAT GAC GCA TTG 
ACC C (3, fixed region containing a Bam H1 site). The design of the oligonucleotides 
was similar to the procedure as described by Berglund et al. (1997) with a template 
containing 40 randomized nucleotides and with two restriction sites, Eco R1 and Bam 
H1. PCR was performed with 200pM template in 500^il of l^iM primer 1，l^iM 
primer 2, 0.2mM dNTPs, 1.5mM MgCl2, 1 x PCR buffer (20mM Tris-HCl, pH 8.4， 
and 50mM KC1), and Tag DNA polymerase. Twenty cycles were done at the 
following temperatures: 9 4 � C for lminute, 6 0 � C for 30 seconds, and lTC for 30 
seconds. PCR products (Sel-DNA 0 to 15, named according to the number of SELEX 
cycles) were confirmed and purified by 2% agarose gel electrophoresis. 
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4.2.2.2 Preparation ofRNA Pools 
The templates generated from the PCR reaction was used for in vitro 
transcription using T7 RNA polyermase. The first RNA pool was generated from 20 
of standard transcription reactions. Each tube contained 20 \x\ reaction mixture with 1 
^g of Sel-DNA as template, transcription buffer (0.04 M Tris-HCl, pH8.0, 6mM 
MgCl2, lOmM DTT, 2mM spermidine), 0.5mM ATP, 0.5mM CTP, 0.5mM GTP, 
0.5mM UTP, 40 units of T7 RNA polymerase, 0.75mg/ml BSA and 20 units of RNase 
inhibitor. The mixture was incubated overnight (-16 hours) at 37°C. The remaining 
DNA template was removed by digestion with 20 units DNase I, RNase-free solution 
for 15 minutes at 37�C. The RNA was extracted with an equal volume of 25:24:1 
phenol/chloroform/isoamylalcohol, precipitated by 70% ice-cold ethanol, and 
collected by 30 minutes centrifugation at 4 � C . The random pool of RNA was 
generated with the following sequence CCU CUG UCA GGC UCG G(N)40 CCC 
AGU UAC GCA GUA U. Usually, an amount of approximately 5^g of RNA was 
synthesized from 1 i^g of DNA template. The RNA pools of the second and 
subsequent generations were prepared under the similar conditions. 
4.2.2.3 In vitro Selection ofRNA Ligands 
RNA ligands that bind to HIV-1 PR were isolated by using protein A-agarose 
immunoprecipitation method. 
104 
Protein A-agarose slurry was first pre-washed in washing buffer (50mM Tris 
HC1, pH 4.7，150mM KC1, 0.05% Nonidet P-40) to remove contaminants from the 
bead slurry. 
In the first six rounds, the bead slurry were pre-incubated with HIV-1 PR IgG 
antibodies for 2 hours at 4°C. The beads were then washed three times with the 
washing buffer. Approximately 0.02|j^g of tRNA was added and pre-incubated onto 
the beads, in order to block the non-specific RNA binding sites from the beads. 
The binding of RNA pools generated from 4.2.2.2 with HIV-1 PR was 
performed in a binding buffer consisted of 50mM Tris-HCl (pH 4.7), 5mM NaCl, 
5mM MgCl2, 14mM KC1, lmM DTT. Binding of the RNA pool to HIV-1 PR was 
done at 37°C for 10 minutes. Afterward, the protease-RNA mixture was incubated 
with the antibody-beads (pre-treated with tRNA) at 4 � C for 2 hours with rotation. The 
beads were then washed by the washing buffer several times. The protease bound 
RNAs were eluted from heated for 3 minutes at 95°C. After phenol extraction and 
ethanol precipitation, 2/3 of the RNA was used for reverse transcription. 
In the final nine rounds, two aliquots of the pre-washed bead slurry were 
prepared. For the first aliquot, RNA pool from previous in vitro transcription was 
added, and incubated for 10 minutes at 3TC. The beads were pelleted and the 
supernatant was then incubated with HIV-1 PR. Then the pre-filtered RNA-protease 
bound was applied to the second aliquot, followed the procedure stated above for in 
vitro selection. 
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The conditions for washing were at low stringency in the first few rounds of 
selection. The conditions of stringency, then, gradually increased in order to select 
wider ranges of RNA aptamers. In the initial three rounds, the concentration of KC1 in 
washing buffer was 150mM. After every other rounds, the concentration of KC1 was 
increased to 0.9M in the round 15. The concentration of HIV-1 PR present in the first 
round of selection was O.lmM. After every other round, the concentration of HIV-1 
PR was lowered until in the final round of selection (fifteen round), HIV-1 PR was at 
O.lpM. During these selections, the stringency was progressively increased by 
increasing ratio of protein:RNA (by decreasing the concentration of protease), 
increasing the concentration of KC1 in washing buffer. Detailed incubation and 
washing conditions were shown in Table 4.2. 
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Table 4.2: In vitro selection of RNAs that bind to HIV-1 PR. The binding was carried 
out at 37°C for 10 minutes. 
Round Pool RNA HrV-1 PR Concentration Frequency of 
(pM) of salts washing 
1 10 O.lmM 150mM 3 
2 10 lO i^M 150mM 5 
3 10 l^M 150mM 5 
4 10 O.l^iM 250mM 5 
5 10 lOnM 300mM 5 
6 10 lnM 300mM 5 
7 10 O.lnM 350mM 5 
8 10 lOpM 400mM 5 
9 10 lpM 600mM 5 
10 10 O.lpM 650mM 5 
11 10 O.lpM 700mM 5 
12 10 O.lpM 750mM 5 
13 10 O.lpM 800mM 5 
14 10 O.lpM 850mM 5 
15 10 O.lpM 900mM 5 
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4.2.2.4 Reverse Transcription Reaction ofSelected RNA 
The selected protein-bound RNA obtained from the immunoprecipition 
procedure was reverse transcribed with THERMOSCRffT'" reverse transcription kit 
(GffiCO BRL, Life Technologies) with a 3' primer (5,-GCG GGA TCC TAT GAC 
GCA TTG TCC C-3'). The transcribed cDNA was used as template for PCR 
amplification as described in section 4.2.2.1. The PCR product was then transcribed 
with T7 RNA polymerase to generate an enriched RNA pool for used in the next 
round ofSELEX. 
4.2.2.5 Cloning ofthe Amplified cDNA pools 
The sequences of the RNA aptamers were identified by cloning of the 
amplified cDNAs with the following primers: 5'-GCG GGA TCC TAT GAC GCA 
TTG TCC C-3' and 5,-GCG GGA TCC TAT GAC GCA TTG TCC C-3,. The PCR 
products were cut with Eco R1 and Bam H1 (GffiCOL BRL, Life Technologies), and 
then subcloned into pBluescript® II KS (-)• The ligated plasmids were transformed 
into E.coli strain DH5a. 
4.2.2.6 Suhcloning ofthe digested DNA product into pBluescript® II KS (-) 
The digested DNA products were first subcloned into the pBluescript® II KS 
(-) .T4 ligase enzyme (Gibco BRL) was used. An ratio of 3:1 (insert:vector) was 
prepared and the incubation with T4 ligase at 16�C ovemight in the presence of T4 
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ligase buffer (supplied together with T4 ligase enzyme from Gibco BRL). After the 
ligation, the ligated product was transformed into DH5a competent cell. 
The transformed bacterial colonies were picked for the preparation of plasmid 
DNA for auto DNA sequencing using the MegaBACE DNA Sequencer. A DNA 
primer, corresponding to the sequence of the T7 promoter 5'- TAA TAC GAC TCA 
CTA TAG GG -3', or the T3 promoter 5'- AAT TAA CCC TCA CTA AAG GG - 3' 
was used as the sequencing primer. Sequences were analyzed and aligned using the 
Clustalw Sequence Analysis Software (European Bioinformatics Institute). 
4.2.2JRNA Labeling with Digoxigenin (DIG) 
The non-radioactive DIG system using digoxigenin, a steroid hapten, was 
employed to label the RNA products. To produce DIG-labeled RNA, the selected 
DNA is transcribed in vitro with T7 RNA polymerases in the presence of DIG-UTP 
labeling mix. The procedure for DIG-labeling is similar to that for in vitro 
transcription as described before, except the 0.5mM UTP is replaced to 0.5mM DIG-
labeled-UTP. The in vitro transcription was using DIG RNA Labeling Kit (Roche-
Boehringer Mannheim). The DIG-labeled RNA was then used for binding affinity 
assay. 
4.2.2.8 Binding Affinity ofRNA Ligandsfor HIV-1 PR 
The binding affinity of selected RNA ligands was measured by protein A-
Agarose immunoprecipitation method mentioned above, however, using DIG-labeled 
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selected RNA. RNA (10 ^M) from round 0 and round 15 was bound to HIV-1 PR that 
typically ranged in concentration from 10"^ ^ to 10"^  M. Protease and DIG-labeled 
RNA were incubated at 37°C for 10 minutes in binding buffer. After binding RNA to 
HIV-1 PR, in vitro selection was followed the procedure mention in 4.2.2.3. The 
binding affinity was detected by direct sandwich ELISA using chemiluminescent 
detection system with CDP-Star®. Diluted specific anti-HIV PR antibody solution 
(lO^ig/ml) was coated onto a 96-well plate with bicarbonate coating buffer at 37°C 
overnight. The plate was washed with wash buffer (1 x PBS, and 0.05% Tween-20) 
three times. The non-specific sites were blocked by incubating the plate with blocking 
buffer (1 X PBS, 0.2% BSA, and 0.05% Tween-20) for 2 hours at 37°C, and then 
incubated with the pre-incubated DIG-labeled RNA-HIV-1 PR reaction mixture. After 
incubation, the mixture was washed with wash buffer. Afterward, an anti-DIG-
alkaline-phosphatase (AP) was added, and incubated for 1 hour with shaking at room 
temperature. After washing with wash buffer, 50 p,l of CDP-Star substrate was added 
per well and incubated for 1 hour at room temperature with shaking. The 
cheminumince generated by CDP-Star® was measured in a luminescence detector (|Li 
Quant Biomolecular Spectrophotometer). 
The standard curves for DIG-RNA from pool 0, 6 and 15 were constructed by 
directly coating known concentration of the standard DIG-labeled RNA onto a 
positive charged microtiter plate (NUNC™). A various concentration of standard 
DIG-labeled RNA (10"^^ to 10'^ ) was coated onto the positive charged plate in the 
presence of 20mM Tris-HCl (pH 7.5) and 20mM EDTA for 2 hours at 3TC, then 
stored overnight at 4°C. The plate was washed with wash buffer three times. Then 
followed the procedure similar to the ELISA assay described above. 
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4.2.2.9 Competition Binding Reactions 
The binding activity of individual RNA aptamers for HIV-1 PR was measured 
by competition binding assay using DIG-labeled RNA on an ELISA assay. A DIG-
labeled RNA was transcribed with T7 RNA polymerase as described in section 
4.2.2.7. An amount of 0.1|iM (apparent Kd of the RNA from 15'^  round) of DIG-
labeled RNA (ligand 15.1) was incubated with various concentrations RNAs 
identified as high affinity aptamers (10]o to 10'^  M). The mixed RNAs were then 
bound to lnM HFV-1 PR and were incubated for 10 minutes at 37°C. Protein A-
agarose immunoprecipitation was used to separate free from RNA bound protein. 
The competition binding activity between DIG-labeled RNA and non-DIG-
labeled RNA was detected by direct sandwich ELISA using chemiluminescent 
detection system with CDP-Star® mentioned above (section 4.2.2.8). 
The standard curve for bound ligand 15.1 constructed by directly coating 
known concentration of the ligand 15.1 onto a positive charged microtiter plate 
(NUNC™). An amount of O.lp,M of ligand 15.1 was coated onto the positive charged 
plate in the presence of 20mM Tris-HCl (pH 7.5) and 20mM EDTA for 2 hours at 
37°C, then stored ovemight at 4°C. The plate was washed with wash buffer three 
times. Then followed the procedure similar to the ELISA assay described above. 
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4.2.2.10 HIV-1 PR InhibitoryActivities ofthe SelectedRNA Ligands 
The inhibitory activities of the selected RNA on HIV-1 PR was determined by 
using fluorometric assay mentioned in Chapter 2. An amount of lO i^M of RNA (from 
round 0，and round 15) was incubated with l^iM HIV-1 PR in the presence of assay 
buffer with addition of RNase inhibitor included the composition by DECP-water). 
The reaction was carried out by incubation at 37°C for one hour. The fluorescence 
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4.3.2 Sequences of RNA Ligands 
All sequences of RNA ligands obtained after 15 rounds of SELEX against 
HIV-1 PR are listed in Table 4.3 (with their binding affinity, ranged between lnM to 
0.9^iM). Eighty-seven clones were subjected to autosequencing for the deduction of 
RNA aptamers from the 15'^  round of SELEX. Table 4.3 shows the sequences have 
high frequency of nucleotide base. 
4.3.3 Binding Affinity of RNA Ligands 
Figure 4.2 compared the binding affinity of RNA ligands from round 0, 6’ and 
15. Once RNA aptamers comprise a significant fraction of a selected pool, each 
successive cycle of selection and amplification is expected to give an increase in the 
binding affinity for the protein target. From the figure, the binding affinity was 
increased with the number of cycle of SELEX processes increased. The binding 
affinity of the round 0 RNA for HIV-1 PR was low, while the binding affinity of 
RNA pools for HIV-1 PR after successive round of in vitro selection revealed a steady 
improvement in affinity. By round 15, the dissociation constant (Kd), the protein 
concentration at which 50% of maximal RNA binding occurs, of the selected RNA 
aptamers is 0.1|jM. 
Figure 4.3 showed the binding affinity of individual RNA aptamer with high 
frequency from round 15 (ligand 15.1, ligand 15.2 and ligand 15.3 in Table 4.3). 
114 
6出 Round ‘ 
Clone Name Sequences (-40N-) Kd 
(nM) 
6.1(5) -AGAGAAAUUUAGAGAAGGGCCAAAGGGGAUUGGGUCUCGC-““1 
6.2(2) -AGAGAAGGACGGAUAAGGGCAACCAUAUGAACUCUCCAAA- 3 
6.3 -CCUCUGGGCAGUGCGCGGACCUAAGGAUGGCUCUAAGACG- 500 
6.4 -CCCAGUUACGCAGUAUGGGUAGGCGGCUAUCCUCUGUCAG- 600 
6.5 -CCAAACACGCAAGAAUGGGCGGCCUCAAAAACUCUGCAGU- 200 
6.6 -AACCUCUACAGACAAUGGGAGUGCUCAAAUUACAAGCAGA- 80 
6.7 -AAGCUCUGGCACCUCGGGAUCGUAGGAGUGCGCUCUGUAG- 80 
6.8 -AACUCUUGUACCAGACGGGCUUAUACCGAGCGAGGAUAUG- 80 
6.9 CAGAACUAUCAAACAAAGGGCAAUGUAACCAAACGUGUUA- 700 
6.10 -CAGCACUCUCCAACUAAUUCGGGUGGACUAAUUCGUCCGC- 300 
6.11 -GUAGACUCUGAUUAACGGGUCUUCGUUAGCAACCAGGCGC- 300 
6.12 -UUCAGUUCCCACGCUAGGGAUAUAGCCUUAAAGGCUCUCA- 900 
6.13 -ACAAACUCUGCCUACAUACGGGCACACGAUAAGCCAUGCG- 30 
6.14 -AAGCGAUAUCCGCCAAUAUGGGCUCGGGCCUCUCUCUAAC- 20 
6.15 -AGAACUAUCAAACAAAGGGCAAUUGGGCCAAACGUGUUAC- 20 
6.16 -AACUCUUGGAAUGUUGGGUAUAGAUAUAAAUACGACCACG- 70 
6.17 -AGAACCCGCAAACAAAGGGCAAUUGGGCCAAACCUCUUAA- 80 
6.18 -AAUGCGGAGUCAACCCAGUGCGAAAACAGAUACAAAGAAC- 80 
6.19 -GCCAAACACGCAAGAAUGGGCCGGCCUCAAAAACUCUGCA- 400 
6.20 -GGGGCCGGACAAAUGCGGGCCAGAACUAUUCUCUGCCAUG- 400 
6.21 -AUUCUCUUGAGCCAGAGAAACUACAAACAUCCGUCUGGCU- 60 
6.22 -AAUCAUAUUGAGCCAGAGUAAAUACAACAUCCCUCUGGCU- 60 
6.23 -ACCCAAUUUAGAGGGAGGUCCUAAGCGGAUUCCGGCCCGC- 50 
6.24 -AUCCCAAAGUAAAAUCAGGGUACUUACCCACUGUUUAUGG- 80 
6.25 -AGAGAAGGACCGAUAGGGACUUCCAUAAUGAACACGCCAG- 50 
6.26 -CAGCACCUCCCAAGGGAUUCGCCUGGACUAAUUCGUCCGC- 100 
6.27 -CGAUCCACGCUCGCGAGGGUGCACUGCAAGAAGAGGGGGU- 100 
6.28 -CCGGACAUUAGACAAGGGAAAAGCUCGGUCGGCCCGUCGG- 500 
6.29 -AUCCCAAAGUAAAAUGGGUAUACUUACCCACUGUUUAUGG- 70 
6.3 0 -GAACUCAGCAACCGCACGAGGGUAAUCAGUCGCCCCCUCC- 300 
i5th Round 
Clone Name Sequences (-40N-) Kd 
(nM) 
15.1 (15) -AGAGAAAUUUAGAGAAGGGCCAAAGGGGAUUGGGUCUCGC- 1 
15.2(9) -AGAGAAGGACGGAUAAGGGCAACCAUAUGAACUCUCCAAA- 3 
15.3(9) -AGAGAUCCGGACGGGAGCCGGGUUAGGGAAUCUCGAGUGC- 10 
15.4(2) -AACCACGCGUGCGGCGCCGGGUUCGACUAGGAUCUCACCC- 70 
15.5 -GCCAAACACCGAGUCUGGGCGGCCUCAAAUAAAAAGCAGG- 300 
15.6 -AGAGAAGGACCCAUAGGGACAUCCAUAAUGAACACGCCAG- 30 
15.7 -CAGCACCUCCCAACUAGGGCGCCUGGACUAAUUCGUCCGC- 900 
15.8 -UAGGUGUAACCGCUGGGCCGGUAUUCGGAUUCCGGCCCGG- 100 
15.9 -ACCCAAUUUUAGCCCGGGUCCUAAGCGGAUUCCGGCCCGC- 90 
15.10 -GCCAAACACCGGGGUCUUGGCGGCCUCAAAUAAAAAGCAG- 100 
15.1 1 -CAGUUGGACGCUGCGGGCAUAGCCUUAAAGCAUCUCAGGG- 200 
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15.12 -CCAAACACCGGGGUCUUGGCGGCCUCAAAUAAAAAGCAGG- 200 
15.13 -AAGAUCUCGCCGGCGGUGGGGCCACCUCGAGGUUCUCCGG- 70 
15.14 -GGUUAUCCGGCUUUAGGGGUUAAAGGGAAUAUCUCGUUCG- 200 
15.15 -AGCAUAAUGUUAAGUGGGCGGCAGCAAAAUGUUUCUCCAC- 60 
15.16 -CCGGGGGAGUCAGCUGGGAUAGCUAUCGACUAUCUCUUCG- 500 
15.17 -CGAACUAUAGCUUAGGGUAUGAUGAGUGAUAUCCUCUCGC- 500 
15.18 -CUCGGUAACUUCCGGGUAACCAUCAAAGAUAAUCUCUCGC- 300 
15 • 19 -AACAAUUAGUCGAGUGGGGAAUUGGUUAUCCGGCUCUCGC- 60 
15.20 -UCUAUCCCAACUCACAACAGGGUCGGGCCUUGUUCUCAGG- 100 
15.2 1 -GGUUAUCCGGCUUUAGGGGUCCUAGGGAAUAUUUCUCUCC- 100 
Control Sequences 
Clone Name Sequences (-40N-) Kd 
(nM) 
N6.1 -ACCUCCGGCCGGACCAAUUGUGAUCACAUUGCGACUCGGA-~~8^~ 
N6.2 -GCGAUUGAUUAAGGUUACAAUCAACGUCCCGUACUGCUUA- 600 
N6.3 -CAGCACCCGACAAUCCGAUUCGGGUGGACUCCCUCGUCCG- 500 
N6.4 -AGAUAAGUACACUCCGACCGUUGGUCCGAACAGGCUCGCG- 300 
N6.5 -CAACCUCCACUCCUGAAUCAAAGACUAAUAAUCUAGACAU- 700 
N15.1 -AUGCGGAGUCAACCCAGUGCGAAAACAGAUACAAAGAACC- 800 
N15.2 -GCGGUGUGCCCUUAUCAGGGCCAAAUAUAAGGCUCUACCA- 600 
N15.3 -CCGGUCAUUAGACAAAAAAAAAGCUCGGUCGGCCCGUCGU- 900 
N 15.4 -ACCCAAUUUUAGCCCAGGUCCUAAGCGGAUUCCGGCCCGC- 800 
N15.5 -UCAGGCUCGCGAUAUCAGGUAACUCGCUGCGGUGCUCUGA- 600 
N15.6 -CGUGUAGGGGGAAAGCGGUCGACCGCAUUAUCGCUUCUCC- 700 
B6.1 -GGCGAAAAAUGACAUCGUGCGUCCCAGCGUCCGAGCGUCC- 600 
B6.2 -CAAACAGGCGUGCCACCGUUCGGCAUAACAAAAAUUAAAA- 300 
B6.3 -GGCUCUGACGCCCUACGGGCAAAACUAUUCCCGCCCAUGA- 700 
B15.1 -AUUCUCUUGAGCCAGAGAAACUACAAACAUCCGUCUGGCU- 600 
B15.2 -GCAUACCGGCCCCCGCGUUCCCCACCCAUACUUCUUAUUA- 600 
B15.3 -AGAGAAGGACCCAUAGCGACUUCCAUAAUGAACACGCCAG- 500 
B15.4 -CAGCACCUCCCAACUAAUUCGCCUGGACUGGUUCGUCCGC- 300 
B 15.5 -CGAUCCACGCUCGCGAUUCCGCACUGCAAGAAGAGGGGGU- 200 
B 15.6 -UCUAUCCCAACUCACAACAAGGUCAACCUUGUUCUCAGGU- 300 
B15.7 -UUGCAGCACUGACCCUUUUCCCACCGCAAUCGGUUGAAUU- 600 
Table 4.3: RNA aptamers isolated from SELEX. The first number refers to the 
round of the SELEX procedure from which the ligand was isolated. The 
number after is a clone designation number. The sequence of the selected 
region of each ligand is shown. The entire ligand also includes the 5，and 3’ 
fixed regions as designated in Material and Methods. For the control group 
sequences, 'N' refers to the non-specific binding control (i.e. using non-
specific antibody for immunoprecipitation; 'B' refers to the BSA control 
group. The sequences were analysized by using the Clustalw Sequence 
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Figure 4.2: Binding of selected RNA pools to HIV-1 PR. RNA pools from rounds 0，6 
and 15 of in vitro selection were bound to various concentration of HIV-1 PR. RNA 
(lO^iM) was bound to HIV-1 PR that ranged in concentration from 10"^ ^ to 10"^  M. 
HIV-1 PR and RNA pools were incubated at 37°C for 10 minutes. In vitro selection 
was carried out according to the methods mentioned in Material and Methods. Values 
means 土 S.E.M with n=3. 
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Figure 4.3: Binding of cloned RNA ligands to HIV-1 PR with high frequency (ligand 
15.1, ligand 15.2, ligand 15.3 shown in Table 4.3). RNA prepared from cloned RNA 
ligands was bound to varying concentrations of HIV-1 PR from lO^iM to lOOpM. The 
procedure was carried out as described in Materials and Methods, competition assay 
section. Values are means 土 S.E.M with n=3. 
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4.3.4 Inhibitory Activity of RNA Ligands 
One of the purposes of these experiments was to find inhibitory ligands to 
HIV-1 PR. We compared the ability of the RNA ligands after 15 rounds of SELEX 
selection with the starting RNA population (round 0) to inhibit PR activity (Table 4.4) 
by fluorometric assay described before. At equal concentrations (l^iM) of inhibitor 
RNA to HIV-1 PR, the PR is significantly inhibited by RNA ligands from the 15'^  
rounds in vitro selection. Thus, affinity is correlated with inhibition. 
The inhibitory activity on HIV-1 PR by individual RNA ligands from 15'^  
rounds selection was also tested. However, very little inhibitory activity was found 
(Table 4.5). Therefore, the high activity ligand for the inhibitory activity is still not 
identified from the pool. 
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Rounds % of Inhibition 
- 52.75 ± 2.53 
15 72.72土1.11 
Table 4.4: The inhibitory activities of pool of RNAs from round 0 and round 15. An 
amount of \\LM of RNA from the pool was added into 10)jM of fluorogenic substrate, 
and then incubation one hour. The fluorescence intensity was measured at an 
excitation wavelength 340nm and emission wavelength 490nm. Detailed procedures 
for determination of HIV-1 PR activities were mentioned in Chapter 2. Values are 
means 土 S.E.M with n=3. 
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Clone Name % Inhibition 
Ligand 15.1 8.53±1.35 
Ligand 15.2 5.06土1.75 
Ligand 15.3 5.58±0.83 
Table 4.5: The inhibitory activities of ligand 15.1, ligand 15.2 and ligand 15.3 showed 
in Table 4.3. An amount of l^iM of RNA from the pool was added into 1 0幽 of 
fluorogenic substrate, and then incubation one hour. The fluorescence intensity was 
measured at an excitation wavelength 340nm and emission wavelength 490nm. 
Detailed procedures for determination the activities of HIV-1 PR were mentioned in 
Chapter 2. Appendix III listed the inhibitory activities of all individual selected RNA 
ligands. The dissociation constant (Kd) was also showed in this table. Values are 
means 土 S.E.M with n=3. 
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4.4 Discussion 
The SELEX is a powerful technique for the isolation of high-affinity ligands 
to a target protein from a pool of variant nucleic acid sequences (Tuerk and Gold, 
1990). The selected high affinity RNA ligands have already been shown as inhibitors 
against HIV-1 protein Rev, Tat, RT, and ^ (Allen et aL, 1995; Giver et al., 1993; 
Lochrie et aL, 1997; Schneider et aL, 1995; Tuerk and Waugh, 1993). 
We carried out SELEX experiment by the use of an RNA pool that contained a 
region of 40 random base pairs nucleotides flanked at both ends of the constant 
regions. The length of random 40 base pairs have been shown to be sufficient to 
identify aptamers that bind tightly to a target molecule (Askari and McDonnell, 1996). 
The SELEX techniques are generally designed to screen for high-affinity 
binding ligands while avoiding the accumulation of non-specific binding ligands 
(Tuerk and Gold, 1990). The key factor that affects the selection of high-affinity 
aptamers is the stringency of the selection. Selections that are not stringent enough 
would not discriminated high affinity from low affinity. In my study, a non-
amplifiable, competitor molecule, tRNA, was introduced in order to saturate any non-
specific binding sites or to compete with the low affinity pool of RNA. tRNA is often 
used in almost all of the SELEX. Another consideration is to systematically reduce 
the target concentration or increase the stringency of washing at each round of 
SELEX are commonly used in almost all of the SELEX. For example, Berglund et aL, 
(1997) used SELEX to identify high affinity RNA ligands that bind HIV-1 
nucleocapsid protein. They increased the selection stringency by lowering the RNA 
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and protein concentration at each round of selection, and increasing the concentration 
of competitor tRNA at the last three rounds of SELEX. In our experiment, from round 
7 to final round (15^^ round), the RNA pool was pre-absorbed first with protein A-
agarose beads in order to select against RNAs that bound to the beads. 
As shown in Table 4.3’ the RNA sequences with high frequency of occurrence 
identified in reaction against HIV-1 PR but not in that of the control SELEX in which 
no HIV-1 PR is present. There were two sequence motifs found in this collection of 
sequences. One sequence motif that was found is that a consensus AGAGA sequence 
followed by AAU or AGG. All the sequences that have this motif (representing 41 of 
the 87 sequences of experiment) are with AGAGA at the beginning of the sequence, 
and also with UCUC element at the near end of the sequence. Thus sequences that 
contained this motif were found to bind with high-affinity to HIV-1 PR (Kd = lnM 
for ligand 15.1’ Kd « 3nM for ligand 15.2, and Kd « lOnM for ligand 15.3). Ligand 
15.1 differs from other two (ligand 15.2 and 15.3) at the position where the more 
frequency poly-AAA and poly-GGG are occurred. These three ligands also showed 
the highest inhibitory activities ( - 8 . 5 % , � 5 . 1 % � a n d � 5 . 6 % respectively) on HIV-1 PR 
among other selected sequences, although the inhibitory activities exhibited are not 
significantly high as compared to that from pools of RNA from round 0 (-53%) and 
round 15 (~ 73%). 
The second motif is a repeated element of AAA, UUU, and GGG. This motif 
was found in almost all of the sequences. It revealed that these sequences exhibit 
significant retention on HIV-1 PR. Many of the sequences from both control groups 
experiment (non-specific antibodies binding group and BSA protein binding group) 
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does not shown those repeated elements (Table 4.3). For example, the sequences of 
ligand N15.3 and ligand 6.28 showed the similar sequences except ligand N15.3 does 
not contain GGG. As compared to the similar experiment done by Tuerk et al. (1992) 
on the HIV-1 RT using nitrocellulose filter binding assay, sequences that showed high 
affinity to HIV-1 RT with homo-purine (AAA and GGG) found to have significantly 
high retention on nitrocellulose filter, even without the presence of protein. In my 
study, the homo-purine sequences were not frequently found in the control SELEX in 
the absence of the HIV-1 PR. It indicated that in vitro selection by 
immunoprecipitation technique avoid the over presentation of homo-purine sequence 
motifs would have occurred in the filter binding assay. 
It is interesting to note that some subsitution of nucleotides in a sequences 
would favor the interaction of RNA to HIV-1 PR (i.e. decreasing the dissociation 
constant). For example, comparing the sequences between ligand 6.15 and ligand 
6.17，a replacement in U-C, U-G, and G-C would decrease the Kd from 0.8|iM 
(ligand 6.17) to 0.2|iM (ligand 6.15), indicating that the nucleotide -G- at this position 
is crucial for the binding to HIV-1 PR. 
It was noticed that the frequency of occurrence of repeated elements of AAA 
or GGG in the RNA aptamers are positively co-related with the binding affinity to 
HIV-1 PR. And the presence of purines (A and G) may be essential for the binding on 
HIV-1 PR. However, the actual binding mechanism and the interaction on HIV-1 PR 
responsible for the binding are still uncleared. 
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The inhibitory activity of selected RNA ligands after 15 rounds of in vitro 
selection is increased as compared to that of RNA pools before any selection. 
However, we failed to find out the main sequence pattem(s) of the RNA aptamers that 
is (are) responsible for the inhibitory activities. It may because we have just 
characterized 87 RNA aptamers sequences, which is just a small size from the RNA 
pools. Therefore, the chance to pick up a sequence that shows the highest inhibitory 
activity is low. 
One of the objective of the present SELEX analysis was to search for RNA 
aptamers that would inhibit the HIV-1 PR activity. Preliminary analysis suggested 
that although the selected RNAs exhibited high affinity binding, they generally have 
marginally inhibitory activity on HIV-1 PR. The results indicated that the selected 
RNA aptamers appear not directly competing with the substrates binding site found in 
this study. 
The SELEX technology provides a powerful method for the screening of large 
libraries of oligonucleotides, which diversities of up to 10^ ^ different molecules, for 
specific ligand-binding nucleic acids which in many cases have been shown not only 
to bind a certain target protein, but also to inhibit its biological function (Conrad et 
al, 1996; frvine et al., 1991). Many isolated aptamers are aimed at possible 
therapeutic and/or diagnostic applications (Ellington and Conrad, 1995; Kraus et al., 
1998). Insufficient stability, often cited as the major potential drawback of nucleic 
acids as therapeutic agents, can easily be overcome by using libraries of chemically 
modified nucleic acids, for example using 2'-amino, and 2'-fIuoro-2'-
deoxyribonucleotide RNA as potent inhibitor (Pieken et al., 1991). 
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The diagnostic applications of RNA aptamers are promising. The SELEX 
method may well be a fast, general method for producing drugs with clinical efficacy. 
In fact, the possible clinical usage of aptamers has been reported. The RNA aptamers 
have been applied to both ELISA-like assays and fluorescence-activated cell sorter 
analyses have been done with aptamers (Davis et al, 1996). 
Aptamers for antibodies is one of the main targets in this field of research. 
Single-stranded DNA and 2'-amino-modified RNA molecules which bind human IgE 
have been isolated by in-vitro selection (Wiegand et al, 1996). Truncated aptamers 
(designated as IGEL1.2 -2'amino RNA- and D17.4 -ssDNA-) were shown to 
competitively inhibit the interaction of human IgE with its FceRI receptor in rat 
basophilic leukemia cells transfected with the human IgE receptor. The 
oligonucleotides block the IgE-mediated release of biogenic amines, such as 
serotonin, which is an important mediators in allergic responses. Because of these 
properties, the selected aptamers may have the potential to serve as a class of new 
therapeutics for the therapy of allergic diseases. 
In 1995’ RNA sequences, which mimicked a major autoantigenic epitope of 
the human insulin receptor, were isolated and were of potential used in the treatment 
of patients with extreme insulin resistance type B (Doudna et al, 1995). The selected 
aptamers showed cross-reactivity with the insulin receptor-like autoantibodies and 
were shown to serve as RNA decoys, with the effect that the aptamers protected the 
insulin receptor from antibody binding. 
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Cancer therapy is another potential application. Jellinek et. al. (1993) reported 
the isolation of nuclease-resistant 2'amino-modified RNA inhibitors of basic 
fibroblast growth factor (bFGF). This growth factor initiates angiogenesis by binding 
to either heparin proteoglycans or tyrosine kinase receptor on the surfaces of 
endothelial cells. Over-expression of this factor is correlated with many malignant 
disorders. The selected aptamer was extensively characterized and was demonstrated 
to bind to bFGF with a dissociation constant of 350pM, reducing the expression level 
of bFGF (Jellinek et aL, 1993). 
An over-expression of another member of the FGF family, human 
keratinocyte growth factor (hKGF) was also shown to participate in many malignant 
disorders. In 1997, Pagratis et. al selected nuclease-resistant 2,-amino- and 2'-fluoro-
2'-deoxyribonucleotide-modified RNA inhibitors for hKGF. The isolated hKGF 
aptamers bind hKGF with an dissociation constant up to -0.3pM (Pagratis et al, 
1997). 
In conclusion, the potential application of oligonucleotide aptamers in the 
clinical area and academic research is promising (Ellington and Conrad, 1995; Kraus 
et aL, 1998). High affinities and specificities of aptamer/target-interactions can 
routinely be found and the techniques can be adapted for high throughput automation. 
Furthermore, a wide spectrum of chemical modifications of nucleotides is known 
which greatly increase the stability of RNA molecules in biological materials, 
considerably enhancing their application potential (Pieken et al., 1991; Green et al., 




The rapid emergence in the last decade of AE)S as a health threat of global 
significance has fostered extensive research of HIV in order to develop effective 
therapies. Although, a huge amount of money, manpower, times and energy have been 
dedicated to research on anti-HIV compounds, ADDS is still a disease with no curable 
medication. Several drugs have been clinically approved by FDA and prescribed for 
AEDS patient since 1987. However, the efficacy of these drugs is limited by the 
development of toxicity and drug resistance problems, which continue to be the 
undesirable consequences of administration of some the drugs. 
Therefore, alternative therapies have been used by some of the AE)S patient to 
rescue their life. The use of natural products is one of the common alternative therapies. 
Many research papers have already showen that a spectacular diversity of chemical 
structures encompassing proteins, terpenoids, alkaloids, coumarins, xanthones, flavones, 
flavonoids, polyphenols, steryl glycosides and polysaccharides were capable of inhibiting 
HIV replication and/or activities of HIV enzymes (RT, PR, or JN) (Vlietinck et aL, 
1998). 
In this project on isolation of HIV-1 PR inhibitors, we first used the starting 
material medicinal herbs, which have been proven to be effective as antiviral materials, in 
view of the finding that compounds derived from plant sources may possess the 
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advantage of reduced toxicity as compared with Westem drugs. In the parallel 
experiment, RNA ligands were in vitro selected as antisense oligonucleotide drugs. 
In the first part of the identification of the active constituent(s) from Chinese 
medicinal herbs, two extraction methods were used, aqueous and methanol. Gel filtration 
on Sephadex LH-20 and reverse phase HPLC were used to purified the active 
principle(s). The bioassay was carried by using a fluorogenic peptide, and further 
confirmed the inhibitory activities by using a synthetic peptide that mimic the cleavage 
site of HIV-1 PR. From the preliminary screening of 31 medicinal herbs, we found out 
that methanol extract of Woodwardia unigemmata shown high inhibitory activities, 
which leading our attention to further purify and characterize the active constituents from 
the herbs. Actually, the effective concentration of Woodwardia unigemmata methanol 
extract is similar to those reported by Wan et aL (1996) and screening of traditional 
medicine currently used for treatment of various human diseases in China, Japan and 
Indonesia (Xu et aL, 1996). Finally, we successfully isolated a HPLC purified compound 
that shown significant anti-HIV-1 PR activity from the methanol extract of Woodwardia 
unigemmata. The proposed chemical property of the active constituent is a 
glycoalkaloids-like compound and the proposed molecular mass is about 6kDa. However, 
further characterization is necessary in the way to determine the chemical structure by 
NMR and to understand the action mechanism activities of the active constituent. The 
toxicity of the compound should also be determined. In vivo studies on H9 cell line 
should be carried out if it is available. 
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For the second part of my research, an in vitro selected RNA ligands would be 
isolated in order to bind and inhibit the viral enzyme protease (Tuerk and Gold, 1990). In 
developing nucleic acid ligand strategies against viral diseases, SELEX procedures will 
be invaluable in rapidly identifying the most promising sequence. It provided 
combinatorial libraries as a powerful tool to find out the specific ligands. Libraries 
selected for binding to mixtures of targets potentially contain ligands to many epitopes 
that are inaccessible to traditional antibody technology. Unlike antibodies, these libraries 
are not biased by natural mechanisms such as immune tolerance. And, thus the related 
ligands may be developed as drugs to treat a variety of diseases (Pan et al, 1995). In 
addition, such RNAs may be useful against serum targets as is illustrated by the evolved 
DNA ligands inhibitory to thrombin (Boch et. aL, 1992). 
A conserved sequence AGAGA with minimal Kd ~ lnM was selected by our 
experiment based on the ability of immunopreciptation by specific antibodies for HIV-1 
PR (raised by ourselves). Another motif sequences (AAA and GGG) was also determined 
to show the specific ability for RNA ligands to bind to HIV-1 PR. Although we 
successfully showed the specific binding affinity of the selected RNA ligands on HFV-1 
PR, the RNA ligands responsible for the inhibition action on the protease still un-
identified. In this study, further characterization of those selected RNA ligands should be 
carried out such as ligand boundary determinations, truncated and mutated RNA ligands 
determination. Chemical modification of the selected RNA ligands should be carried out 
because it is essential for the nuclease-resistance. 
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To conclude, the research on anti-HIV compounds, both natural and synthetic, 
still need great effort, times, and manpower. Therefore, the most powerful cures of AH)S 
still are the prevention and education. 
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